**Alessia Cimadamore**



|  |  |
| --- | --- |
| **Personal**  **Information** | Date of Birth: 30/09/1989  CF: CMDLSS89P70I324A  Citizenship: Italian  ORCID: 0000-0001-5981-3514 |
| **Contact**  **Information** | [alessiacimadamore@gmail.com](mailto:alessiacimadamore@gmail.com)  alessia.cimadamore@uniud.it |

**Position**

|  |  |
| --- | --- |
| October 31 2022- current | **Research Fellow** type B, SSD MED/08 Anatomia patologica, 06/A4, Department of Medical Area, **Udine University, Udine, Italy**  **Surgical pathologist,** Institute of Pathological Anatomy,Ospedale Santa maria della Misericordia, Udine, Itay |
| August 1 2020-October 30 2022 | **Research Fellow** type A, SSD MED/08 Anatomia patologica, 06/A4, Department of Biomedical Sciences and Public Health, **Polytechnic University of Marche Region, Ancona, Italy**  **Surgical pathologist,** SOD Anatomia Patologica,Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Italy.   * Core member of the Prostate Unit Multidisciplinary Group * Core member and foundator of the Molecular Tumor Board |

**Education**

|  |  |
| --- | --- |
| Jan 31,2022-2031 | **National Scientific Qualification for tenured Associate Professorship in the sector 06/A4 – Pathological Anatomy** |
| November 2018- March 2022 | **Ph.D.,** Biomedical Sciences, **Polytechnic University of the Marche Region, Ancona, Italy**   * Thesis title: Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Randomized Phase III METEOR Trial * Advisor: Rodolfo Montironi, MD, Head, Genitourinary Cancer Program, Full Professor of Pathological Anatomy |
| 2015- 2019 | **Residency**, Pathological Anatomy and Histopathology, **Institute of Pathological Anatomy and Histopathology**, United Hospitals, Ancona(affiliated with Alma Mater Studiorum, Bologna University)   * Thesis Topic: *Diagnostic, prognostic and predictive value of immunohistochemical molecular subtyping of bladder cancer.* * Advisor: Rodolfo Montironi, MD, Head, Genitourinary Cancer Program, Full Professor of Pathological Anatomy * Research Supervisor: Antonio Lopez-Beltran, Full-Professor of Anatomic Pathology, Córdoba University Medical School, Director of Anatomic Pathology, Champalimaud Clinical Center, CCU, Lisbon, Chairman, European Working Group on Urologic Pathology (ESP) * *110/110 Summa Cum Laude* |
| 2008 - 2014 | **Medical degree**, **Faculty of Medicine and Surgery**, **Polytechnic University of the Marche Region**, Ancona, Italy   * Thesis Topic: *New histochemical and immunohistochemical markers useful for differential diagnosis of adrenocortical carcinoma: phospho-histone H3 antibody for mitosis count.* * Advisor: Prof. Marina Scarpelli, MD, Director of Pathological Anatomy Department, Full Professor of Pathological Anatomy * *110/110 Summa Cum Laude* |
| 2013-2014 | **Internship, Department Surgical Pathology Anatomy, United Hospital, Ancona.** |

**Research Experience**

|  |  |
| --- | --- |
| Sep 2020-current | **External Collaborator, Dana Farber Cancer Institute, Boston, MA, USA** |
| Nov 2019- June 2020 | **Post-Doc Research Fellowship, Brigham and Women's Hospital, Department of Pathology, Harvard Medical School, Boston, MA, USA**   * Research Project: SPORE Project 4:Identification of Biomarkers of durable response to PD-1 Blockade in ccRCC and nccRCC patient samples. * Correlative Biomarkers Project: CheckMate025, METEOR, AtezoBev, OMNIVORE, Rare GU, HCRN GU16-260, PROSPER trials. * Research Advisor**:** Prof. Sabina Signoretti, Full Professor of Pathology, Harvard Medical School, Boston, MA, USA. |
| Sep 2017 | Visiting resident at **Pathology Department of Champalimaud Clinical Centre**. Lisbon. Supervisor: Prof. Antonio Lopez Beltran. |
| Feb- Jun 2015 | **Oncoxx Biotech, Chieti University.**  Research Assistant, Ce.S.I.   * Research Project: *p-53 mutations analysis in metastatic breast cancers.* |

**Awards**

* **International Society of Urologic Pathology (ISUP) Stipend Award**, on the basis of his past and ongoing career interest in Genitourinary Pathology – United States and Canadian Academy of Pathology (USCAP) Annual Meeting, Los Angeles– Feb 28, 2020.
* **Best Abstract di Sessione 2021 Prostate Cancer – Surgical Management. 94° Congresso Nazionale SIU Riccione 2021.** Focal secondary resection of neurovascular bundles after digital frozen section of prostate surface: a novel tailored surgical approach. M.C. Sighinolfi, L. Sarchi, S. Assumma, **A. Cimadamore**, R. Montironi, L. Reggiani Bonetti, F. Turri, C. De Carne, A. Maiorana, S. Micali, B. Rocco. SC8
* **Best abstract Awards ‘GUPS Award for Excellence in Uropathology Research’ (1st prize),** submitted by a trainee to the **USCAP Annual Meeting 2021. Co-Author of** Abstract: Whole Slide Microvascular Density (MVD) Evaluation in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC): Association With ISUP/WHO Grade, PD-L1 Expression, and Mast Cell I (ID: 889). March 2021
* Medical Sciences Award for the **BEST PATHOLOGY FELLOW** based on the study/research in genito-urinary diseases. GENITO URINARY TRACT TUMORS Florence, 31st May - 1st June, 2018.
* 1st classified at 5th World top communications of the year in Genito-Urinary Oncology. Arezzo Nov 16-18 2016

**Publications**

188 publications from 2016 to 2023, 174 indexed in PubMed: 46 as first author, 12 as co-first author, 24 as second, 5 as corresponding author, 103 as collaborator.

Number of citations on Google Scholar: 2133.

H index: Scopus 18, Web of Science 17, Google Scholar 24.

1. Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace DJ, Signoretti S, Denize T, **Cimadamore A**, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. *Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)*. J Immunother Cancer. 2023 Mar;11(3):e004780. doi: 10.1136/jitc-2022-004780. PMID: 36948504; PMCID: PMC10040058.
2. Cheng L, Lopez-Beltran A, Wang M, Whaley RD, De Souza A, Au S, Ge R, **Cimadamore A**, Amin A, Golijanin B, MacLennan GT, Osunkoya AO, Montironi R, Zhang S. *Frequent Telomerase Reverse Transcriptase (TERT) Promoter and Fibroblast Growth Factor Receptor 3 (FGFR3) Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder*. Mod Pathol. 2023 Mar 9:100151. doi: 10.1016/j.modpat.2023.100151.
3. Raspollini MR, Comperat EM, Lopez-Beltran A, Montironi R, **Cimadamore A**, Tsuzuki T, Netto GJ. *News in the classification of WHO 2022 bladder tumors*. Pathologica. 2023 Jan 25. doi: 10.32074/1591-951X-838. Epub ahead of print. PMID: 36704871.
4. **Cimadamore A**, Lopez-Beltran A, Cheng L, Montironi R. *Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification*. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015. Eur Urol. 2022 Dec 12:S0302-2838(22)02843-3. doi: 10.1016/j.eururo.2022.11.024. Epub ahead of print. PMID: 36517350.
5. **Cimadamore A**, Caliò A, Marandino L, Marletta S, Franzese C, Schips L, Amparore D, Bertolo R, Muselaers S, Erdem S, Ingels A, Pavan N, Pecoraro A, Kara Ö, Roussel E, Carbonara U, Campi R, Marchioni M; EAU-YAU Renal Cancer Working Group. *Hot topics in renal cancer pathology: implications for clinical management.* Expert Rev Anticancer Ther. 2022 Nov 15. doi: 10.1080/14737140.2022.2145952. Epub ahead of print. PMID: 36377655.
6. Man YG, Mannion C, Jewett A, Hsiao YH, Liu A, Semczuk A, Zarogoulidis P, Gapeev AB, **Cimadamore A**, Lee P, Lopez-Beltran A, Montironi R, Massari F, Lu X, Cheng L. *The most effective but largely ignored target for prostate cancer early detection and intervention.* J Cancer. 2022 Oct 17;13(13):3463-3475. doi: 10.7150/jca.72973. PMID: 36313040; PMCID: PMC9608211.
7. Del Giudice F, D'Andrea D, Pradere B, Berndl F, Pallauf M, Flammia RS, Philipp D, Moschini M, Mari A, Albisinni S, Krajewski W, Laukhtina E, Gallioli A, Mertens LS, Marcq G, **Cimadamore A**, Afferi L, Gontero P, Shariat SF, Chung BI, Soria F. *Surgical checklist adherence across urology expertise levels impacts TURBT quality indicators*. BJU Int. 2022 Oct 17. doi: 10.1111/bju.15920. Epub ahead of print. PMID: 36251366.
8. Collins K, Sholl LM, Siegmund S, Dickson BC, Colecchia M, Michalová K, Hwang M, Ulbright TM, Kao CS, van Leenders GJLH, Mehta V, Trpkov K, Yilmaz A, **Cimadamore A**, Matoso A, Epstein JI, Maclean F, Comperat E, Anderson WJ, Fletcher CDM, Acosta AM. *Myoid Gonadal Stromal Tumors are Characterized by Recurrent Chromosome-Level Copy Number Gains: Molecular Assessment of a Multi-Institutional Series.* Histopathology. 2022 Oct 13. doi: 10.1111/his.14825. Epub ahead of print. PMID: 36226695.
9. Montironi R, **Cimadamore A**, Mazzucchelli R, Lopez-Beltran A, Scarpelli M, Cheng L. *Histopathology of Prostate Cancer and its Precursors.* Appl Immunohistochem Mol Morphol. 2022 Oct 11. doi: 10.1097/PAI.0000000000001067. Epub ahead of print. PMID: 36222497.
10. Montironi R, **Cimadamore A**. *Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity.* Eur Urol. 2022 Aug 10:S0302-2838(22)02548-9. doi: 10.1016/j.eururo.2022.07.032.
11. Marletta S, Fusco N, Munari E, Luchini C, **Cimadamore A**, Brunelli M, Querzoli G, Martini M, Vigliar E, Colombari R, Girolami I, Pagni F, Eccher A. *Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems*. J Pers Med. 2022 Jun 29;12(7):1073. doi: 10.3390/jpm12071073.
12. Krajewski W, Aumatell J, Subiela JD, Nowak Ł, Tukiendorf A, Moschini M, Basile G, Poletajew S, Małkiewicz B, Giudice FD, Maggi M, Chung BI, **Cimadamore A**, Galosi AB, Fave RFD, D'Andrea D, Shariat SF, Hornak J, Babjuk M, Chorbińska J, Teoh JY, Muilwijk T, Joniau S, Tafuri A, Antonelli A, Panunzio A, Alvarez-Maestro M, Simone G, Mastroianni R, Łaszkiewicz J, Lonati C, Zamboni S, Simeone C, Niedziela Ł, Candela L, Macek P, Contieri R, Hidalgo BG, Rivas JG, Sosnowski R, Mori K, Mir C, Soria F, González-Padilla DA, Faba ÒR, Palou J, Ploussard G, Rajwa P, Hałoń A, Laukhtina E, Pradere B, Tully K, Burgos FJ, Cidre MÁJ, Szydełko T; European Association of Urology- Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. *Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.* Urol Oncol. 2022 Jul 15:S1078-1439(22)00227-7. doi: 10.1016/j.urolonc.2022.06.008.
13. **Cimadamore A**, Teoh JY, DI Trapani E, Krajewski W, Tan WS, Mori K, Del Giudice F, Carrion DM, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. *A gender-related dichotomy in bladder cancer*. Minerva Urol Nephrol. 2022 Jun;74(3):376-378. doi: 10.23736/S2724-6051.22.04954-0.
14. Santoni M, Massari F, Rizzo A, Mollica V, **Cimadamore A**, Montironi R, Battelli N. *Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis*. Tumori. 2022 May 20:3008916221090323. doi: 10.1177/03008916221090323.
15. Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, Hurwitz M, Peace DJ, Signoretti S, Denize T, **Cimadamore A,** Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. *Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A*). J Clin Oncol. 2022 Apr 20:JCO2102938. doi: 10.1200/JCO.21.02938.
16. Laukhtina E, Moschini M, Soria F, Andrea DD, Teoh JY, Mori K, Albisinni S, Mari A, Krajewski W, **Cimadamore A**, Abufaraj M, Enikeev D, Neuzillet Y, Giannarini G, Xylinas E, Kamat AM, Roupret M, Babjuk M, Witjes JA, Shariat SF, Pradere B; European Association of Urology; Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group; European Association of Urology Section of Oncological Urology ESOU. *Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group*. Eur Urol Focus. 2022 Mar 22:S2405-4569(22)00058-X. doi: 10.1016/j.euf.2022.03.004. Epub ahead of print. PMID: 35337773.
17. Lorenzoni M, De Felice D, Beccaceci G, Di Donato G, Foletto V, Genovesi S, Bertossi A, Cambuli F, Lorenzin F, Savino A, Avalle L, **Cimadamore A**, Montironi R, Weber V, Carbone FG, Barbareschi M, Demichelis F, Romanel A, Poli V, Del Sal G, Julio MK, Gaspari M, Alaimo A, Lunardi A. *ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradation.* Cancer Lett. 2022 Mar 5;534:215612. doi: 10.1016/j.canlet.2022.215612. Epub ahead of print. PMID: 35259458.
18. Stangl-Kremser J, Muto G, Grosso AA, Briganti A, Comperat E, Maida FD, Montironi R, Remzi M, Pradere B, Soria F, Albisinni S, Roupret M, Shariat SF, Minervini A, Teoh JY, Moschini M, **Cimadamore A**, Mari A; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. *The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis*. Urol Oncol. 2022 Feb 28:S1078-1439(22)00032-1. doi: 10.1016/j.urolonc.2022.01.014. Epub ahead of print. PMID: 35241364.
19. **Cimadamore A,** Lonati C, Di Trapani E, De Cobelli O, Rink M, Zamboni S, Simeone C, Soria F, Briganti A, Montorsi F, Afferi L, Mattei A, Carando R, Ornaghi PI, Tafuri A, Antonelli A, Karnes RJ, Colomer A, Sanchez-Salas R, Contieri R, Hurle R, Poyet C, Simone G, D'Andrea D, Shariat SF, Galfano A, Umari P, Francavilla S, Roumiguie M, Terrone C, Hendricksen K, Krajewski W, Buisan O, Laukhtina E, Xylinas E, Alvarez-Maestro M, Rouprêt M, Montironi R, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. *Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?* Urol Oncol. 2022 Feb 22:S1078-1439(22)00026-6. doi: 10.1016/j.urolonc.2022.01.008. Epub ahead of print. PMID: 35216892.
20. Marchetti A, Rosellini M, Nuvola G, Tassinari E, Mollica V, Rizzo A, Santoni M, **Cimadamore A**, Farolfi A, Montironi R, Fanti S, Massari F. PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming? Cancers (Basel). 2022 Feb 11;14(4):907. doi: 10.3390/cancers14040907. PMID: 35205654; PMCID: PMC8869833.
21. Al-Obaidy KI, Saleeb RM, Trpkov K, Williamson SR, Sangoi AR, Nassiri M, Hes O, Montironi R, **Cimadamore A**, Acosta AM, Alruwaii ZI, Alkashash A, Hassan O, Gupta N, Osunkoya AO, Sen JD, Baldrige LA, Sakr WA, Idrees MT, Eble JN, Grignon DJ, Cheng L. *Recurrent KRAS mutations are early events in the development of papillary renal neoplasm with reverse polarity.* Mod Pathol. 2022 Feb 12. doi: 10.1038/s41379-022-01018-6.
22. Lopez-Beltran A, Blanca A**, Cimadamore A,** et al. *T1 bladder carcinoma with variant histology: pathological features and clinical significance* [published online ahead of print, 2022 Feb 4]. Virchows Arch. 2022;10.1007/s00428-021-03264-6. doi:10.1007/s00428-021-03264-6
23. **Cimadamore, A**., Cheng, L., Lopez-Beltran, A., Scarpelli, M., & Montironi, R. *Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles*. Pathology, research and practice 2021;229,153737. <https://doi.org/10.1016/j.prp.2021.153737>
24. Mollica, V., Marchetti, A., Rosellini, M., Nuvola, G., Rizzo, A., Santoni, M., **Cimadamore, A**., Montironi, R., & Massari, F. *An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT*. International journal of molecular sciences, 2021;22(24), 13519. <https://doi.org/10.3390/ijms222413519>
25. Denize T, Farah S, **Cimadamore A,** et al. *Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial*. Clin Cancer Res. 2021;clincanres.3088.2021. doi:10.1158/1078-0432.CCR-21-3088
26. Morelli, M. B., Amantini, C., Rossi de Vermandois, J. A., Gubbiotti, M., Giannantoni, A., Mearini, E., Maggi, F., Nabissi, M., Marinelli, O., Santoni, M., **Cimadamore, A**., Montironi, R., & Santoni, G. *Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer*. Cancers,2021;13(23), 5989.
27. **Cimadamore A,** Lopez-Beltran A, Scarpelli M, Cheng L, Montironi R. *Artificial Intelligence and Prostate Cancer: Advances and Challenges*. Urologia. 2021 Dec 8:3915603211062409. doi: 10.1177/03915603211062409.
28. Murrone A., Cantini L., Pecci F., Cognigni V., Copparoni C., Rinaldi S., Fiordoliva I., Monaco F., Rubini C, Barbisan F, **Cimadamore A**., Giampieri R., Bianchi F., Tomasetti M., Amati M., Santarelli L., Berardi, R. *BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma*. Journal of thoracic disease, 2021, 13(10), 5741–5751. <https://doi.org/10.21037/jtd-21-555>
29. Lopez-Beltran A, Blanca A, **Cimadamore A**, Gogna R, Montironi R, Cheng L. *Molecular classification of bladder urothelial carcinoma using the NanoString-based gene expression analysis.* Cancers (Basel). 2021 Nov 1;13(21):5500. doi: 10.3390/cancers13215500.
30. Laukhtina, E., Shim, S. R., Mori, K., D'Andrea, D., Soria, F., Rajwa, P., Mostafaei, H., Compérat, E., **Cimadamore, A**., Moschini, M., Teoh, J. Y., Enikeev, D., Xylinas, E., Lotan, Y., Palou, J., Gontero, P., Babjuk, M., Witjes, J. A., Kamat, A. M., Roupret, M., … European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group (2021). *Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis*. European urology oncology, S2588-9311(21)00183-8. Advance online publication. https://doi.org/10.1016/j.euo.2021.10.003
31. Aurilio G, Santoni M, Massari F, **Cimadamore A**, Rizzo A, Mollica V, Verri E, Battelli N, Montironi R. *Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views*. Cancers (Basel). 2021 Oct 18;13(20):5229. doi: 10.3390/cancers13205229.
32. Montironi R, Lopez-Beltran A, **Cimadamore A**, Cheng L, Scarpelli M. *Leading expert opinion: What's the future in uropathology.* Urologia. 2021 Oct 6:3915603211049884. doi: 10.1177/03915603211049884. Epub ahead of print. PMID: 34612741.
33. Rocco B, **Cimadamore A**, Sighinolfi MC, Assumma S, Montironi R. *Reply to Eoin Dinneen, Jon Oxley, and Greg Shaw's Letter to the Editor re: Bernardo Rocco, Luca Sarchi, Simone Assumma, et al. Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.021.* Eur Urol. 2021 Sep 2:S0302-2838(21)01985-0. doi: 10.1016/j.eururo.2021.08.017. Epub ahead of print. PMID: 34483006.
34. **Cimadamore A,** Mazzucchelli R, Lopez-Beltran A, Massari F, Santoni M, Scarpelli M, Cheng L, Montironi R. *Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation.* Cancers (Basel). 2021 Jul 11;13(14):3471. doi: 10.3390/cancers13143471. PMID: 34298683.
35. **Cimadamore A**, Scarpelli M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R. *Digital whole mount sections of the prostate: heading towards new ways of communicating with clinicians and patients without microscope.* Minerva Urol Nephrol. 2021 Jul 15. doi: 10.23736/S2724-6051.21.04552-3.
36. Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, **Cimadamore A**, Santoni M, Montironi R, Massari F. *The molecular characteristics of non clear cell renal cell carcinoma: what’s the story morning glory?* Int J Mol Sci. 2021 Jun 9;22(12):6237. doi: 10.3390/ijms22126237.
37. Montironi R, **Cimadamore A**, Cheng L, Lopez-Beltran A, Scarpelli M. 2021-0221-LE *The Coronavirus Disease 2019 (COVID-19) Pandemic's Impact on Social Interaction in Pathology*. Arch Pathol Lab Med. 2021 Jun 25. doi: 10.5858/arpa.2021-0221-LE. Online ahead of print.
38. **Cimadamore A,** Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. *Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate*. Eur Urol. 2021 Jun 17:S0302-2838(21)01807-8. doi: 10.1016/j.eururo.2021.06.001. Epub ahead of print. PMID: 34148712.
39. **Cimadamore A**, Lopez-Beltran A, Scarpelli M, Cheng L, Montironi R. *Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Bründl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol 2021;4:182-91: Image Analysis, Nuclear Abnormality Index, and Pattern Recognition Analysis.* Eur Urol Oncol. 2021 Jun 15:S2588-9311(21)00117-6. doi: 10.1016/j.euo.2021.06.002. Epub ahead of print. PMID: 34144939.
40. Albisinni S, Moschini M, Di Trapani E, Soria F, Mari A, Aziz A, Teoh J, Laukhtina E, Mori K, D'Andrea D, Carrion DM, Krajewski W, Abufaraj M, **Cimadamore A**, Tan WS, Flippot R, Khalifa J, Gonsette K, Pradere B; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). *Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers.* World J Urol. 2021 Jun 2. doi: 10.1007/s00345-021-03746-x.
41. **Cimadamore A**, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, Scarpelli M, Lopez-Beltran A, Galosi AB, Montironi R. *Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.* Int J Mol Sci. 2021 May 24;22(11):5522. doi: 10.3390/ijms22115522.
42. Santoni M, Tombesi F, **Cimadamore A**, Montironi R, Piva F. *Conceptual Analogies Between Multi-Scale Feeding and Feedback Cycles in Supermassive Black Hole and Cancer Environments.* Front Oncol. 2021 May 11;11:634818. doi: 10.3389/fonc.2021.634818.
43. Montironi R, **Cimadamore A**, Cheng L, Lopez-Beltran A, Scarpelli M. *Lesson from the COVID-19 pandemic: Pathologists need to build their confidence on working in a digital microscopy environment.* Virchows Arch. 2021 May 25. doi: 10.1007/s00428-021-03123-4.
44. Belenchia M, Rocchetti G, Maestri S, **Cimadamore A,** Montironi R, Santoni M, Merelli E. *Agent-Based Learning Model for the Obesity Paradox in RCC.* Front Bioeng Biotechnol. 2021 Apr 29;9:642760. doi: 10.3389/fbioe.2021.642760. eCollection 2021.
45. Montironi R, Scarpelli M, **Cimadamore A**, Mikuz G. Re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017: *Focus on Our Personal Recollections and Observations.* Eur Urol Focus. 2021 May 11:S2405-4569(21)00129-2. doi: 10.1016/j.euf.2021.04.023
46. **Cimadamore A**, Lopez-Beltran A, Scarpelli M, Cheng L, Montironi R. *The wide spectrum of oncocytic changes and tumors in the kidney: splitting and lumping.* Pathobiology. 2021 May 11:1-4. doi: 10.1159/000516046.
47. Rocco B, Sarchi L, Assumma S, **Cimadamore A**, Montironi R, Reggiani Bonetti L, Turri F, De Carne C, Puliatti S, Maiorana A, Pellacani G, Micali S, Bianchi G, Sighinolfi MC. *Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique.* Eur Urol. 2021 May 5:S0302-2838(21)00227-X. doi: 10.1016/j.eururo.2021.03.021.
48. **Cimadamore A**, Rizzo A, Mollica V, Massari F, Lopez-Beltran A, Scarpelli M, Cheng L, Santoni M, Montironi R. *Update on immunotherapy in uro-oncology.* Expert Review of Precision Medicine and Drug Development: Editorial. 2021; doi.org/10.1080/23808993.2021.1911638
49. Lopez-Beltran A, **Cimadamore A**, Montironi R, Cheng L. *Molecular Pathology of Urothelial Carcinoma*. Hum Pathol. 2021 Apr 19:S0046-8177(21)00052-6. doi: 10.1016/j.humpath.2021.04.001
50. Mollica V, Rizzo A, Di Nunno V, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, **Cimadamore A**, Montironi R, Massari F. *Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?* Transl Androl Urol. 2021 Mar;10(3):1581-1587. doi: 10.21037/tau-20-1125.
51. Rocco B, **Cimadamore A**, Sarchi L, Reggiani Bonetti L, Bertoni L, Azzoni P, Assumma S, Turri F, Puliatti S, Eissa A, Micali S, Bianchi G, Maiorana A, Montironi R, Pellacani G, Sighinolfi MC. *Current and future perspectives of digital microscopy with fluorescence confocal microscope for prostate tissue interpretation: a narrative review*. Transl Androl Urol. 2021 Mar;10(3):1569-1580. doi: 10.21037/tau-20-1237.
52. Santoni M, **Cimadamore A**, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, Battelli N, Montironi R. *Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States*. Transl Androl Urol. 2021 Mar;10(3):1562-1568. doi: 10.21037/tau-20-1439
53. Rizzo A, Mollica V, **Cimadamore A**, Santoni M, Scarpelli M, Schiavina R, Cheng L, Lopez-Beltran A, Brunocilla E, Montironi R, Massari F. *TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?* Transl Androl Urol. 2021 Mar;10(3):1541-1552. doi: 10.21037/tau-20-1109.
54. Montironi R, Cheng L, **Cimadamore A,** Mazzucchelli R, Scarpelli M, Santoni M, Massari F, Lopez-Beltran A. *Prostate cancer grading systems: Will the Gleason Scores be replace by the Grade Groups?* Transl Androl Urol. 2021 Mar;10(3):1530-1540. doi: 10.21037/tau-20-853.
55. Aurilio G+, **Cimadamore A**+\*, Lopez-Beltran A, Scarpelli M, Massari F, Verri E, Cheng L, Santoni M, Montironi R. *Narrative review: Update on immunotherapy and pathological features in patients with urothelial bladder cancer.* Transl Androl Urol. 2021 Mar;10(3):1521-1529. doi: 10.21037/tau-20-1436.
56. **Cimadamore A**, Cheng L, Scarpelli M, Massari F, Mollica V, Santoni M, Lopez-Beltran A, Montironi R, Moch H. *Towards a new WHO classification of renal cell tumor: What the clinician need to know.* Transl Androl Urol. 2021 Mar;10(3):1506-1520. doi: 10.21037/tau-20-1150.
57. **Cimadamore A**, Cheng L, Scarpelli M, Lopez-Beltran A, Montironi R. *Digital diagnostics and artificial intelligence in prostate cancer treatment in 5 years from now*. Transl Androl Urol. 2021 Mar;10(3):1499-1505. doi: 10.21037/tau-2021-01.
58. **Cimadamore A**, Lopez-Beltran A, Scarpelli M, Montironi R. *Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.01.005*. Eur Urol. 2021 Jun;79(6):e172-e173. doi: 10.1016/j.eururo.2021.03.020.
59. Galosi AB, Palagonia E, Scarcella S, **Cimadamore A**, Lacetera V, Delle Fave RF, Antezza A, Dell'Atti L. *Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology.* Arch Ital Urol Androl. 2021 Mar 22;93(1):92-100. doi: 10.4081/aiua.2021.1.92
60. **Cimadamore A**, Lopez-Beltran A, Scarpelli M, Montironi R. *RE: Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer, by Jones TD and Cheng L, (Low grade papillary intra-urothelial neoplasia)*, Urol Oncol. 2021 Mar 3:S1078-1439(21)00071-5. doi: 10.1016/j.urolonc.2021.02.010.
61. Montironi R, **Cimadamore A**, Scarpelli M, Cheng L, Lopez-Beltran A, Mikuz G. *Let us not forget about our past contributions to the field of prostatic neoplasms: to some extent what we value now was already there.* Pathol Res Pract. 2021 Feb 13;219:153377. doi: 10.1016/j.prp.2021.153377.
62. Santoni M, Miccini F, **Cimadamore A**, Piva F, Massari F, Lopez-Beltran A, Cheng L , Montironi R, Battelli N. *An update on investigational therapies that target STAT3 for the treatment of cancer.* Expert Opinion On Investigational Drugs, Expert Opin Investig Drugs. 2021 Feb 18. doi: 10.1080/13543784.2021.1891222.
63. Montironi R, **Cimadamore A**, Scarpelli M, Cheng L, Lopez-Beltran A. *Queries from a patient with intraductal prostate carcinoma And how two separate uropathology societies deal with IDC-P*. Eur Urol Today, Vol. 33, N.1, pp 14-15, January/February 2021
64. Giulietti M, Cecati M, Sabanovic B, Scirè A, **Cimadamore A**, Santoni M, Montironi R, Piva F. *The role of artificial intelligence in the diagnosis and prognosis of renal cell tumors.* Diagnostics (Basel). 2021 Jan 30;11(2):206. doi: 10.3390/diagnostics11020206
65. Rosellini M, Santoni M\*, Mollica V, Rizzo A, **Cimadamore A**\*, Storti N, Battelli N, Montironi R, Massari F. *Treating prostate cancer by antibody drug conjugates*. Int J Mol Sci. 2021 Feb 4;22(4):1551. doi: 10.3390/ijms22041551.
66. Santoni M, Massari F, Santoni G, **Cimadamore A**, Montironi R, Battelli N. *Re: Human Chimeric Antigen Receptor Macrophages for Cancer Immunotherapy.* Eur Urol. 2021 Feb 3:S0302-2838(21)00064-6. doi: 10.1016/j.eururo.2021.01.025.
67. Mollica V, Rizzo A, Rosellini M, Marchetti A, Ricci AD, **Cimadamore A**, Scarpelli M, Bonucci C, Andrini E, Errani C, Montironi R, Massari F. *Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art*. Cancers (Basel). 2021 Feb 1;13(3):546. doi: 10.3390/cancers13030546
68. Santoni M\*, Massari F, Bracarda S, Procopio G, Milella M, De Giorgi U, Basso U, Aurilio G, Incorvaia L, Martignetti A, Rizzo M, Cartenì G, Grande E, Matrana MR, Crabb SJ, Vau N, Sorgentoni G, **Cimadamore A**, Montironi R, Battelli N. *Body mass index in patients treated with cabozantinib for advanced Renal Cell Carcinoma: a new prognostic factor?* Diagnostics (Basel). 2021 Jan 18;11(1):E138. doi: 10.3390/diagnostics11010138
69. Lopez-Beltran A+, **Cimadamore A+**, Blanca A, Massari F, Vau N, Scarpelli M, Cheng L, Montironi R. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. Cancers (Basel). 2021 Jan 3;13(1):E131. doi: 10.3390/cancers13010131.
70. Montironi R, **Cimadamore A**, Lopez-Beltran A, Cheng L, Scarpelli M. *Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy.* Cells. 2020 Dec 24;10(1):E20. doi: 10.3390/cells10010020.
71. Santoni M\*, Piva F, **Cimadamore A**\*, Giulietti M, Battelli N, Montironi R, Cosmai L, Porta C. *Exploring the spectrum of kidney ciliopathies.* Diagnostics (Basel). 2020 Dec 16;10(12):E1099. doi: 10.3390/diagnostics10121099.
72. **Cimadamore A**, Montironi R, Serni S, Campi R. *Seminal Vesicle Tumor Microenvironment*. Adv Exp Med Biol. 2020;1296:309-318. doi: 10.1007/978-3-030-59038-3\_19. PMID: 34185301.
73. **Cimadamore A**, Scarcella S, Palagonia E, Galosi AB, Dell’Atti L, Montironi R. *Liquid biopsy in Renal Cell Carcinoma: current and future.* Advances in Urological Diagnosis and Imaging - 2020; 3,3
74. Aurilio G\*, **Cimadamore A\*,** Mazzucchelli R, Lopez-Beltran A, Verri E, Scarpelli M, Massari F, Cheng L, Santoni M, Montironi R. *Androgen receptor signaling pathway in prostate cancer: from genetic to clinical studies.* Cells. 2020;9(12):E2653.
75. Piva F, Tartari F, Giulietti M, Aiello MM, Cheng L, Lopez-Beltran A, Mazzucchelli R, **Cimadamore A**, Cerqueti R, Battelli N, Montironi R, Santoni M. *Predicting future cancer burden in the United States by artificial neural networks.* Future Oncol. 2020 Dec 11. doi: 10.2217/fon-2020-0359.
76. Devlies W, Eckstein M, **Cimadamore A**, Devos G, Moris L, Van den Broeck T, Montironi R, Joniau S, Claessens F, Gevaert T. *Clinical actionability of the genomic landscape of metastatic castration resistant prostate cancer.* Cells. 2020 Nov 17;9(11):E2494. doi: 10.3390/cells9112494.
77. Lopez-Beltran A, Montironi R, **Cimadamore A**, Cheng L. *Grading of Chromophobe Renal Cell Carcinoma: Do We Need It?* Eur Urol. 2020 Nov 15:S0302-2838(20)30859-9. doi: 10.1016/j.eururo.2020.11.001.
78. Montironi R, **Cimadamore A**, Lopez-Beltran A, Cheng L, Scarpelli M. Exciting experiences in the “*rocky road to digital diagnostics*” J Clin Pathol 2020 Nov 1;jclinpath-2020-207161. doi: 10.1136/jclinpath-2020-207161.
79. Zong Y, Montironi R, Massari F, Jiang Z, Lopez-Beltran A, Wheeler TM, Scarpelli M, Santoni M, **Cimadamore A**, Cheng L. *Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives.* Eur Urol Focus 2020 Oct 29;S2405-4569(20)30291-1. doi: 10.1016/j.euf.2020.10.007
80. **Cimadamore A**, Cheng L, Scarpelli M, Lopez-Beltran A, Mollica V, Montironi R, Massari F. Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76*: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation.* Eur Urol. 2020 Oct 13:S0302-2838(20)30774-0. doi: 10.1016/j.eururo.2020.09.047.
81. Santoni M, Massari F, Aurilio G, Mollica V, **Cimadamore A**, Lopez-Beltran A, Cheng L, Battelli N, Nolé F, Montironi R. *Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy.* 2020 Oct 1. doi: 10.2217/imt-2020-0144.
82. Montironi R, **Cimadamore A**, Scarpelli M, Cheng L, Lopez-Beltran A, Mikuz G. *Pathology without microscope: From a projection screen to a virtual slide.* Pathol Res Pract. 2020 Sep 2;216(11):153196. doi: 10.1016/j.prp.2020.153196.
83. Saoud R, Heidar NA, **Cimadamore A**, Paner GP. *Incorporating prognostic biomarkers into risk assessment models and TNM staging for prostate cancer*. Cells. 2020 Sep 17;9(9):E2116. doi: 10.3390/cells9092116.
84. Rocco B, Sighinolfi MC, Sandri M, Spandri V, **Cimadamore A**, Volavsek M, Mazzucchelli R, Lopez-Beltran A, Eissa A, Bertoni L, Azzoni P, Reggiani Bonetti L, Maiorana A, Puliatti S, Micali S, Paterlini M, Iseppi A, Rocco F, Pellacani G, Chester J, Bianchi G, Montironi R*. Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study.* Eur Urol Oncol. 2020 Sep 17:S2588-9311(20)30136-X. doi: 10.1016/j.euo.2020.08.009.
85. Rizzo A, Mollica V, **Cimadamore A**, Santoni M, Scarpelli M, Giunchi F, Cheng L, Lopez-Beltran A, Fiorentino M, Montironi R, Massari F. *Is there a role for immunotherapy in prostate cancer?* Cells. 2020 Sep 8;9(9):E2051. doi: 10.3390/cells9092051.
86. **Cimadamore A**, Cheng L, Lopez-Beltran A, Lucianò R, Scarpelli M, Montironi R. *Added clinical significance of large format histology in prostate.* Eur Urol Oncol. 2020 Aug 31:S2588-9311(20)30127-9. doi: 10.1016/j.euo.2020.08.003
87. Cheng L, Mann SA, Lopez-Beltran A, Chovanec M, Santoni M, Wang M, Albany C, Adra N, Davidson DD, **Cimadamore A**, Montironi R, Zhang S. *Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection*. Methods Mol Biol. 2021;2195:31-47. doi: 10.1007/978-1-0716-0860-9\_3.
88. **Cimadamore A**, Montironi R. *The 1996 European Urology Focus on Preneoplastic lesions of the Prostate.* Eur Urol Focus, 2020 Aug 15:S2405-4569(20)30211-X. doi: 10.1016/j.euf.2020.07.005.
89. Montironi R, **Cimadamore A**. *Considerations on current and future issues related to reproducibility and accuracy in prostate cancer grading*. Virchows Arch. 2020 Aug 17. doi: 10.1007/s00428-020-02913-6.
90. Mollica V, Maggio I, Lopez-Beltran A, Montironi R, **Cimadamore A**, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. *Combination therapy in advanced urothelial cancer: backgroung and role of PARP, HER-2 AND mTOR inhibitors.* Expert Review of Anticancer Therapy, 2020 Aug 6. doi: 10.1080/14737140.2020.1807334.
91. **Cimadamore A,** Lopez-Beltran A, Scarpelli M, Cheng L, Montironi R. *Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC.* J Clin Pathol. 2020 Jul 30:jclinpath-2020-206943. doi: 10.1136/jclinpath-2020-206943.
92. Cantini L, Pecci F, Murrone A, Tomasetti M, Copparoni C, Fiordoliva I, Morgese F, Rinaldi S, Mazzanti P, Rubini C, **Cimadamore A**, Barbisan F, Giampieri R, Scarpelli M, Santarelli L, Berardi R. *Questioning the prognostic role of BAP-1 immunohistochemistry in advanced mesothelioma patients: a single center experience with systematic review and meta-analysis.* Lung Cancer. 2020 Jun 21;146:318-326. doi: 10.1016/j.lungcan.2020.06.024
93. **Cimadamore A\***+, Aurilio G+, Nole' F, Massari F, Scarpelli M, Santoni M, Lopez-Beltran A, Cheng L, Montironi R. *Update on Circulating tumor cells in genitourinary tumors with focus on prostate cancer.* Cells. 2020;9(6):E1495. doi: 10.3390/cells9061495.
94. Aurilio G\*, **Cimadamore A**, Santoni M, Nole' F, Scarpelli M, Massari F, Lopez-Beltran A, Cheng L,Montironi R. *New frontiers in prostate cancer treatment: are we ready for drug combinations with novel agents?* Cells. 2020;9(6):E1522. doi: 10.3390/cells9061522.
95. Santoni M, Massari F, Cheng L, **Cimadamore A**, Scarpelli M, Montironi R, Lopez-Beltran A. *PD-L1 inhibitors for the treatment of prostate cancer.* Curr Drug Targets. 2020 Jun 9. doi: 10.2174/1389450121666200609142219.
96. Rocco B, Sighinolfi MC, **Cimadamore A**, Reggiani Bonetti L, Bertoni L, Puliatti S, Eissa A, Spandri V, Azzoni P, Dinneen E, Shaw G, Nathan S, Micali S, Bianchi G, Maiorana A, Pellacani G, Montironi R. *Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins.* BJU Int. 2020 May 13. doi: 10.1111/bju.15108.
97. Paner GP, **Cimadamore A**, Darrell CM, Tretiakova MS, Montironi R. *Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy?* Diagnostic Histopathology,2020,doi.org/10.1016/j.mpdhp.2020.04.003.
98. Montironi R, Scarpelli M, **Cimadamore A**, Cheng L, Lopez-Beltran A. *Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance*, Eur Urol. 2020 May 11:S0302-2838(20)30338-9. doi: 10.1016/j.eururo.2020.04.070.
99. **Cimadamore A**, Massari F, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Moch H. *PD-1 and PD-L1 inhibitors for the treatment of kidney cancer: the role of PD-L1 assay.* Curr Drug Targets. 2020 Mar 24. doi: 10.2174/1389450121666200324151056.
100. Gevaert T, **Cimadamore A**, Montironi R, Eckstein M. *PD-L1 testing for urothelial carcinoma: Interchangeability, reliability and future perspectives.* Curr Drug Targets. 2020 May 9. doi: 10.2174/1389450121666200510015216.
101. Raspollini MR, Montagnani I, Cirri P, Baroni G, **Cimadamore A**, Scarpelli M, Cheng L, Lopez-Beltran A, Montironi R, Barnea ER.. *PreImplantation Factor (PIF) Immunohistochemical Expression Correlates with Prostate Cancer Aggressiveness*. IJBM, 2020 May,doi.org/10.1177/1724600820919969
102. Montironi R\*, **Cimadamore A\***, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L. *Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.* Cells. 2020 Apr 25;9(5):E1073. doi: 10.3390/cells9051073.
103. Raspollini MR, Montironi R, Mazzucchelli R, **Cimadamore A**, Cheng L, Lopez-Beltran A. *pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging*. Virchows Arch. 2020 Apr 15. doi: 10.1007/s00428-020-02808-6.
104. Occhipinti G, Romagnoli E, Santoni M, **Cimadamore A**, Sorgentoni G, Cecati M, Giulietti M, Battelli N, Maccioni A, Storti N, Cheng L, Principato G, Montironi R, Piva F. *Sequential or concomitant inhibition of cyclin-dependent kinase 4/6 before mTOR pathway in hormone-positive HER2 negative breast cancer: biological insights and clinical implications.* Front Genet. 2020 Apr 15;11:349. doi: 10.3389/fgene.2020.00349.
105. Montironi R, **Cimadamore A**, Scarpelli M. *From Undergraduate Medical School Student To Visible Pathologist.* Arch Pathol Lab Med. 2020 Apr;144(4):413-414. doi: 10.5858/arpa.2019-0484-LE.
106. Montironi R, **Cimadamore A**, Ohashi R, Cheng L, Scarpelli M, Lopez-Beltran A, Moch H. *Chromophobe renal cell carcinoma aggressiveness and immuno-oncology therapy: how to distinguish the good one from the bad one.* Eur Urol Oncol. 2020 Mar 18:S2588-9311(20)30036-5. doi: 10.1016/j.euo.2020.02.011.
107. Mollica V, Santoni M, Di Nunno V, **Cimadamore A**, Cheng L, Lopez-Beltran A, Battelli N, Montironi R, Massari F. *Immunotherapy and Radiation Therapy in Renal Cell Carcinoma.* Curr Drug Targets. 2020 Mar 11. doi: 10.2174/1389450121666200311121540.
108. **Cimadamore A**, Montironi R, Moch H, Ohashi R. *Re: Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Ohashi R, Martignoni G, Hartmann A, et al. Virchows Arch. 2019 Nov 23. doi: 10.1007/s00428-019-02710-w.* Eur Urol. 2020 Mar 3:S0302-2838(20)30126-3. doi: 10.1016/j.eururo.2020.02.016.
109. Ge R, Wang Z, Montironi R, Jiang Z, Santoni M, Lopez-Beltran A, Massari F, Lu X, **Cimadamore A**, Cheng L. *Epigenetic Modulations and Lineage Plasticity in Advanced Prostate Cancer.* Annals of Oncology ANNONC-2019-1952, Ann Oncol. 2020 Apr;31(4):470-479. doi: 10.1016/j.annonc.2020.02.002.
110. **Cimadamore A**\*, Scarpelli M\*, Massari F, Eckstein M, Gevaert T, Cheng L, Lopez-Beltran A, Montironi R. *Immunotherapy for urothelial cancer: from the diagnostic pathologist’s point of view.* Expert Opin Biol Ther. 2020 Feb 25:1-6. doi: 10.1080/14712598.2020.1733965.
111. AurilioG, SantoniM, **CimadamoreA**, MassariF, Scarpelli M, Lopez-BeltranA, Cheng L, BattelliN, NoléF, MontironiR. *Renal Cell Carcinoma: genomic landscape and clinical implications.* Expert Review of Precision Medicine and Drug Development, 2020, 5:2, 95-100, DOI: 10.1080/23808993.2020.1733407
112. **Cimadamore A**, Scarpelli M, Cheng L, Lopez-Beltran A, Galosi AB, Montorsi F, Montironi R. *Re: Re: EAU Guidelines: Prostate Cancer 2019, Mottet N, van den Bergh RCN, Briers E, et al https://uroweb.org/guideline/prostate-cancer/. Words of Wisdom by Sighinolfi MC, Rocco B. Eur Urol. 2019 Dec;76(6):871* Eur Urol 2020 May;77(5):e122-e127. doi: 10.1016/j.eururo.2020.02.005
113. Montironi R, **Cimadamore A**, Scarpelli M, Cheng L, Lopez-Beltran A. *Examination with the whole-mount section technique. A gallery of ten large-format, histological images of the prostate gland for clinicians.* Eur Urol Today, ESUP section. March-May 2020.
114. Rocco B, Sighinolfi MC, Bertoni L, Spandri V, Puliatti S, Eissa A, Reggiani Bonetti L, Azzoni P, Sandri M, De Carne C, Turri F, **Cimadamore** **A**, Montironi R, Maiorana A, Micali S, Bianchi G, Pellacani G. *Real-time assessment of surgical margin during radical prostatectomy: a novel approach with fluorescence confocal microscopy for the evaluation of peri-prostatic soft tissues.* BJU Int. 2020 Apr;125(4):487-489. doi: 10.1111/bju.15000.
115. Rolim I, Henriques V, Rolim N, Blanca A, Canas Marques R, Volavšek M, Montironi R, **Cimadamore A**, Raspollini MR, Cheng L, Lopez-Beltran A. *Clinico-pathologic analysis of upper urinary tract carcinoma with variant histology.* Virchows Arch. 2020 Jan 16. doi: 10.1007/s00428-020-02745-4.
116. Eckstein M\*, **Cimadamore A\*,** Hartmann A, Lopez-Beltran A, Montironi R Gevaert T. *PD-L1 assessment in urothelial carcinoma. A practical approach.* Ann Transl Med. 2019 Nov;7(22):690. doi: 10.21037/atm.2019.10.24.
117. Montironi R, Cheng L, **Cimadamore A**, Lopez-Beltran A. *Molecular diagnostics in uro-oncology.* Expert Rev Mol Diagn. 2020 Jan 14. doi: 10.1080/14737159.2020.1715799.
118. **Cimadamore A**, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R. *Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.* Future Oncol. 2020;10.2217/fon-2019-0745. doi:10.2217/fon-2019-0745
119. Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Cartenì G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, Verzoni E, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, **Cimadamore A**, Montironi R, Battelli N. *Real-world data on Cabozantinib in previously treated patients with metastatic Renal Cell Carcinoma: focus on prognostic factors and sequences.* Cancers (Basel). 2019 Dec 30;12(1). pii: E84. doi: 10.3390/cancers12010084.
120. Lopez-Beltran A, Cheng L, Gevaert T, Blanca A, **Cimadamore A**, Santoni M, Massari F, Scarpelli M, Raspollini MR, Montironi R. *Current and emerging bladder cancer biomarkers with emphasis on urine biomarkers.* Expert Rev Mol Diagn. 2019 Dec 11:1-13. doi: 10.1080/14737159.2020.1699791.
121. Santoni M, Conti A, Massari F, Di Nunno V, Faloppi L, Galizia E, Morbiducci J, Piva F, Buti S, Iacovelli R, Ferretti B, **Cimadamore A**, Battelli N, Montironi R. *Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies.* Expert Rev Cardiovasc Ther. 2019 Dec 12. doi: 10.1080/14779072.2019.1704626.
122. Aurilio G, Piva F, Santoni M, **Cimadamore A**, Sorgentoni G, Lopez-Beltran A, Cheng L, Battelli N, Nolè F, Montironi R. *The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications.* Int J Mol Sci. 2019;20(22):E5683. doi:10.3390/ijms20225683
123. **Cimadamore A**, Massari F, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R*. Liquid biopsies in Renal Cell Carcinoma with focus on epigenome analysis.* Ann Transl Med. 2019 Sep;7(Suppl 6):S194. doi: 10.21037/atm.2019.07.30.
124. Massari F, Di Nunno V, Mollica V, Montironi R, Cheng L, **Cimadamore A**, Blanca A, Lopez-Beltran A. *Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice.* Immunotherapy. 2019 Dec;11(17):1507-1521. doi: 10.2217/imt-2019-0115.
125. Mollica V , Di Nunno V , Santoni M , **Cimadamore A** , Scarpelli M, Lopez-Beltran A , Cheng L, Mariani C , Battelli N , Montironi R , Massari F. *An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer.* Expert Rev Mol Diagn. 2020 Feb;20(2):207-217. doi: 10.1080/14737159.2019.1684265.
126. Santoni M, Heng D YC, Aurilio G, Iozzelli A, Servi L, Fabiani A, Giannini M, Mazzucchelli R**, Cimadamore A**, Scarpelli M, Zaghloul MS, Battelli N, Montironi R. *Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma.* Curr Drug Targets. 2019 Oct 17. doi: 10.2174/1389450120666191017113051.
127. Kouba E, Lopez-Beltran A, Montironi R, Massari F, Huang K, Santoni M, Chovanec M, Cheng M, Scarpelli M, Zhang J, **Cimadamore A**, Cheng L. *Liquid Biopsy in Clinical Management of Bladder Cancer: Current Status and Future Developments*. Expert Rev Mol Diagn. 2019 Oct 17:1-10. doi: 10.1080/14737159.2019.1680284.
128. Volavšek M, Henriques V, Blanca A, Montironi R, Cheng L, Raspollini MR, **Cimadamore A,** Vau N, Pierconti F, Lopez-Beltran A. *Digital versus light microscopy assessment of extra-prostatic extension in radical prostatectomy samples.* Virchow Archiv, 2019 Oct 7. doi: 10.1007/s00428-019-02666-x.
129. **Cimadamore A,** Scarpelli M, Raspollini MR, Doria A, Galosi AB, Massari F, Di Nunno V, Cheng L, Lopez-Beltran A, Montironi R. *Prostate cancer pathology: what has changed in the last 5 years*. Urologia. 2019 Sep 23:391560319876821. doi: 10.1177/0391560319876821.
130. **Cimadamore A**, Massari F, Santoni M, Mollica V, Di Nunno V, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R , Moch H. *Molecular characterization and diagnostic criteria of Renal Cell Carcinoma with emphasis on liquid biopsies.* Expert Rev Mol Diagn. 2019 Sep 11:1-10. doi: 10.1080/14737159.2019.1665510.
131. Santoni M, **Cimadamore A**, Massari F, Piva F , Aurilio G , Martignetti A, Scarpelli M, Di Nunno V, Gatto L, Battelli N , Cheng L, Lopez-Beltran A, Montironi R. *Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers*. Cancers 2019, 11(9), 1225; https://doi.org/10.3390/cancers11091225
132. Vau N, Henriques V, Cheng L, Blanca A, Fonseca J, Montironi R, **Cimadamore A**, Lopez-Beltran A. Predicting biochemical recurrence after radical prostatectomy*: The role of prognostic grade group and index tumor nodule.* Hum Pathol. (2019) 93, 6–15. pii: S0046-8177(19)30151-0. doi: 10.1016/j.humpath.2019.08.012.
133. Fiordoliva I, Marcantognini G, Rinaldi S, **Cimadamore A**, Montironi R, Berardi R. *Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review.*J Cancer Metastasis Treat 2019;5:59. http://dx.doi.org/10.20517/2394-4722.2019.23
134. **Cimadamore A**, Scarpelli M, Cheng L, Montorsi F, Lopez-Beltran A, Montironi R. *Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, Caroline Moore, Hashim U. Ahmed, Xavier Cathelineau, Mark Emberton, Rafael Sanchez-Salas, Paul Cathcart: Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. European Urology 76 (2019) 27–30. Benefits of morphologic documentation from didactic cases of large format histology.* Eur Urol. 2020 Apr;77(4):e100-e102. doi: 10.1016/j.eururo.2019.07.047.
135. Blanca A, Sanchez-Gonzalez A, Requena MJ, Carrasco-Valiente J, Gomez-Gomez E, Cheng L**, Cimadamore A**, Montironi R, Lopez-Beltran A. *Expression of miR-100 and miR-138 as prognostic biomarkers in Non- Muscle Invasive Bladder Cancer*. APMIS. 2019;127(8):545‐553. doi:10.1111/apm.12973
136. Gevaert T\*, **Cimadamore A**\*, Eckstein M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. *Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go.* Future Oncol. 2019;15(19):2199‐2202. doi:10.2217/fon-2019-0217
137. Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, **Cimadamore A,** Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Massari F. *Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumour*. Cancers (Basel). 2019;11(6):830. doi:10.3390/cancers11060830
138. Di Nunno V, Massari F, Mollica V, **Cimadamore A**, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. *Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma.* Ann Transl Med. 2019 Jul;7(Suppl 3):S137. doi: 10.21037/atm.2019.06.06.
139. Montironi R, **Cimadamore A**, Mazzucchelli R, Scarpelli M, Cheng L, Lopez-Beltran A. *EAU Section of Uropathology (ESUP): Documenting and redefining the spectrum of RCCs. Histological images present wide variety and variants of adult renal epithelial tumours.* Eur Urol Today Jun-Jul 2019
140. Rebola J, Aguiar P, Blanca A, Montironi R, **Cimadamore A**, Cheng L, Henriques V, Lobato-Faria P, Lopez-Beltran A. *Predicting outcomes in nonmuscle invasive bladder cancer (ta/t1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.* Virchows Arch. 2019;475(4):445‐455. doi:10.1007/s00428-019-02593-x
141. Montironi R, Cheng L, Scarpelli M, **Cimadamore A,** Lopez-Beltran A. Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. *Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?* Eur Urol. 2019, 76;e69– e 72. pii: S0302-2838(19)30442-7. doi: 10.1016/j.eururo.2019.05.035.
142. Mollica V, Di Nunno V, Gatto L, Santoni M, **Cimadamore A**, Cheng L, Lopez-Beltran A, Montironi R, Pisconti S, Battelli N, Massari F. *Novel therapeutic approaches and targets currently under evalution for renal cell carcinoma: waiting for the revolution.* Clin Drug Investig. 2019;39(6):503‐519. doi:10.1007/s40261-019-00773-w
143. Montironi R, Santoni M, **Cimadamore A**, Lopez-Beltran A, Cheng L. *Emerging biomarkers in personalized therapy of urologic tumors.* Front Oncol. 2019 Apr 26;9:326. doi: 10.3389/fonc.2019.00326.
144. Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M , Scarpelli M, **Cimadamore A**, Lopez-Beltran A , Cheng L, Battelli N, Montironi R, Brandi G. *The human microbiota and prostate cancer: friend or foe?* Cancers (Basel). 2019 Mar 31;11(4). pii: E459. doi:10.3390/cancers11040459
145. **Cimadamore A,** Santoni M, Massari F, Gasparrini S, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M. *The microbiome in genitourinary tumors.* Front Oncol. 2019 Mar 26;9:178. doi: 10.3389/fonc.2019.00178
146. Santoni M\*, **Cimadamore A\***, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Scarpelli M, Galosi AB, Bracarda S, Montironi R. *Circulating Tumor Cells in Renal Cell Carcinoma: recent findings and future challenges.* Frontiers in Oncology, 5 April 2019, doi: 10.3389/fonc.2019.00228
147. **Cimadamore A**, Gasparrini S, Massari F, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R. *Emerging molecular technologies in renal cell carcinoma: liquid biopsy.* Cancers (Basel). 2019;11(2):196. Published 2019 Feb 7. doi:10.3390/cancers11020196
148. **Cimadamore A**, Scarpelli M, Santoni M, Massari F, Tartari F, Cerqueti R, Lopez-Beltran A, Cheng L, Montironi R. *Genitourinary Tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy*. Curr Drug Metab. 2019;20(4):305‐312. doi:10.2174/1389200220666190225124352
149. Mollica V, Di Nunno V, **Cimadamore A**, Lopez-Beltran A, Cheng L, Santoni M, Scarpelli M, Montironi R, Massari F. *Molecular mechanisms related to hormone inhibition resistance in prostate cancer*. Cells 2019, 8(1), 43; [doi:10.3390/cells8010043](https://doi.org/10.3390/cells8010043)
150. **Cimadamore A**, Santoni M, Cheng M, Lopez-Beltran A, Battelli N, Massari F, Cheng L, Scarpelli M, Montironi R. *New prostate cancer targets for diagnosis, imaging and therapy: emphasis on Prostate-specific membrane antigen.* Front Oncol. 2018 Dec 21;8:653. doi: 10.3389/fonc.2018.00653.
151. Chovanec M, Albany C, Montironi R, **Cimadamore A**, Cheng L. *Emerging biomarkers in testicular germ cell tumors: Looking beyond established practice****.*** Front Oncol. 2018 Nov 28;8:571. doi: 10.3389/fonc.2018.00571.
152. Bianconi M\*, **Cimadamore A\***, Faloppi L, Scartozzi M, Santoni M, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. *Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter*. Ther Adv Urol. 2019;11:1756287218815372. doi:10.1177/1756287218815372
153. **Cimadamore A**, Scarpelli M, Santoni M, Cheng L, Lopez-Beltran A, Montorsi F, Montironi R. Re: Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Haidl F, Pfister D, Heidenreich A. Eur Urol. 2018 Oct;74(4):525-526. *Could the morphologic changes in the periprostatic arteries have an influence on prostatic artery embolization?* Eur Urol. 2019 Apr;75(4):e110-e113. doi: 10.1016/j.eururo.2018.11.026.
154. **Cimadamore A**, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R. *Upper tract urothelial carcinomas: Transition from population to a personalized approach in diagnosis, prognosis and therapy.* Expert Rev Mol Diagn. 2018 Dec;18(12):1021-1028. doi: 10.1080/14737159.2018.1549490..
155. Lopez-Beltran A, Henriques V, **Cimadamore A**, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. *The identification of immunological biomarkers in kidney cancers.* Front Oncol. 2018 Nov 2;8:456. doi: 10.3389/fonc.2018.00456
156. Giunchi F, **Cimadamore A**, Fiorentino M. *Emerging molecular technologies in genito-urinary tumors.* Front Oncol. 2018 Oct 30;8:489. doi: 10.3389/fonc.2018.00489.
157. Saeed O, Lopez-Beltran A, Fisher KW, Scarpelli M, Montironi R, **Cimadamore A**, Massari F, Santoni M, Cheng L. *RAS Genes in Colorectal Carcinoma: Pathogenesis, Testing Guidelines and Treatment Implications*. J Clin Pathol. 2018 Nov 13. pii: jclinpath-2018-205471. doi: 10.1136/jclinpath-2018-205471.
158. Di Nunno V, Gatto L, Santoni M, **Cimadamore A**, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Massari F. *Recent advances in liquid biopsy in patients with castration resistant prostate cancer.* Frontiers in Oncology, 2018;8:397.
159. Massari F, Santoni M, Di Nunno V, **Cimadamore A**, Battelli N, Scarpelli M, Cheng L, Lopez-Beltran A, Montironi R. *Quick steps toward precision medicine in renal cell carcinoma.* Expert Review of Precision Medicine and Drug Development. 3:5, 283-285, DOI: 10.1080/23808993.2018.1510289
160. Lopez-Beltran A, Henriques V, Montironi R, **Cimadamore A**, Raspollini MR, Cheng L. *Variants and new entities of bladder cancer.* Histopathology. 2019;74(1):77-96. doi: 10.1111/his.13752.
161. Montironi R, Cheng L, **Cimadamore A,** Lopez-Beltran A. *Prostate Cancer Grading: Are We Heading Towards Grade Grouping Version 2?* Eur Urol. 2019 Jan;75(1):32-34. doi: 10.1016/j.eururo.2018.07.033.
162. Di Nunno V, Santoni M, **Cimadamore A**, Battelli N, Massari F. *Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. Eur Urol 2018;73:560-9: Tumour, Node, and Metastasis Staging System for Urological Malignancies: Are We Ready for the Next Step?* Eur Urol. 2018 Nov;74(5):e118-e119. doi: 10.1016/j.eururo.2018.06.050.
163. **Cimadamore A**, Scarpelli M, Cheng L, Lopez-Beltran A, Montironi R. *Re: Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. By: Rauscher I, et al. Eur Urol. 2018 May;73(5):656-661.Clinical significance of PSMA immunohistochemistry and role of the uropathologists.* Eur Urol. 2018 Dec;74(6):e141-e144. doi: 10.1016/j.eururo.2018.07.034.
164. **Cimadamore A**, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Giunchi F, Fiorentino M, Scarpelli M, Montironi R. *Biomarkers of aggressiveness in genitourinary tumours with emphasis on kidney, bladder and prostate cancer.* Expert Rev Mol Diagn. 2018:1-11.
165. Piva F, Santoni M, Conti A, Santoni A, Cheng L, Lopez-Beltran A, **Cimadamore A**, Scarpelli M, Battelli N, Montorsi F, Montironi R. *RE: Re: Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91-7. Is this a way to resume or enhance response to immune checkpoint inhibitors in genitourinary tumors?* Eur Urol2018 pii: S0302-2838(18)30422-6.
166. Di Nunno V, Santoni M, Scarpelli M, **Cimadamore A**, Fiorentino M, Cheng L, Lopez-Beltran A, Montironi R, Massari F. *Biological issues related to treatment with Cabozantinib in patients with bone metastatic renal cell carcinoma.* Future Oncol. 2018;14(25):2559-2564.
167. Giulietti M, Santoni M, Carrozza F, Piva F, Cheng L, Lopez-Beltran A, **Cimadamore A**, Scarpelli M, Battelli N, Montironi R. *Exploring small extracellular vesicles for precision medicine in prostate cancer*. Front Oncol. 2018;8:221.
168. Montironi R, **Cimadamore A**, Cheng L, Lopez-Beltran A, Scarpelli M. *Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, biological markers.* Int J Biol Markers. 2018:1724600818781296.
169. **Cimadamore A**, Palagonia E, Piccinni P, Misericordia M, Galosi AB, Montironi R. *Inguinal bladder hernia with lipomatosis of the bladder wall. A potential clinical pitfall for cancer.* Urologia. 2019 Feb;86(1):35-38. doi: 10.1177/0391560319834494.
170. Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, **Cimadamore A**, Martignetti A, Montironi R, Battelli N. *Tivozanib for the treatment of renal cell carcinoma.* Expert Opin Pharmacother. 2018:1-5.
171. Montironi R, Lopez-Beltran A, Cheng L, Zizzi A, **Cimadamore A**, Galosi AB, Berardi R, Scarpelli M. *EAU Section of Uropathology (ESUP): Uropathologists are fast moving forward to include blood (liquid) biopsy in their routine armamentarium*. European Urology Today “in press”
172. Santoni M, Massari F, Di Nunno V, Conti A, **Cimadamore A**, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A. *Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.* Drugs Context. 2018;7:212528.
173. Montironi R, **Cimadamore A**, Gasparrini S, Mazzucchelli R, Santoni M, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M. *Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma.* Expert Rev Anticancer Ther. 2018;18(7):685-693.
174. **Cimadamore A**, Scarpelli M, Cheng L, Lopez-Beltran A, Montironi R. *Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion.* Minerva Urol Nefrol. 2019;71(2):189‐190. doi:10.23736/S0393-2249.18.03145-4
175. Massari F, Santoni M, Di Nunno V, Cheng L, Lopez-Beltran A, **Cimadamore A**, Gasparrini S, Scarpelli M, Battelli N, Montironi R. *Adjuvant and neoadjuvant approaches for urothelial cancer: updated indications and controversies*. Cancer Treatment Reviews 2018;68:80-85.
176. Montironi R, **Cimadamore A**, Massari F, Montironi MA, Lopez-Beltran A, Cheng L, Montorsi F, Scarpelli M. *Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion.* Arch Pathol Lab Med. 2017;141(11):1460-1461.
177. Gasparrini S, **Cimadamore A**, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, Galosi AB, Lopez-Beltran A, Cheng L, Montironi R. *Pathology and molecular updates in tumors of the prostate: towards a personalized approach.* Expert Rev Mol Diagn. 2017;17(8):781-789.
178. **Cimadamore A**, Scarpelli M, Piva F, Massari F, Gasparrini S, Doria A, Cheng L, Lopez-Beltran A, Montironi R. *Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets.* Future Oncol. 2017;13(12):1105-1114.
179. Montironi R, Gasparrini S, **Cimadamore A**, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Briganti A, Scarpelli M. *Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View.* European Urology Supplements. 2017;16(12),223 – 231.
180. Montironi R, Gasparrini S, **Cimadamore A**, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Moch H, Montorsi F, Scarpelli M. *Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View.* European Urology Supplements 2017; 16(12),232–240.
181. **Cimadamore A**, Gasparrini S, Scarpelli M, Doria A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A, Montironi R. *Epigenetic modifications and modulators in prostate cancer.* Crit Rev Oncog. 2017;22(5-6):439-450.
182. Lopez-Beltran A, Cheng L, Raspollini MR, Canas-Marques R, Scarpelli M, **Cimadamore A**, Gasparrini S, Montironi R. *Variants of Bladder Cancer: The Pathologist's Point of View.* European Urology Supplements 2017;16(12) 210-222.
183. Bianconi M, Faloppi L, Lopez-Beltran A, Cheng L, **Cimadamore A**, Gasparrini S, Massari F , Scarpelli M, Montironi R. *Immunotherapy in genitourinary cancers: Where are we going?* Expert Rev Precis Med Drug Dev 2017;2 (2), 73-78. 1321466
184. Montironi MA, Gasparrini S, **Cimadamore A**, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. *RE: Cognitive Algorithms and Digitized Tissue-based Diagnosis. Görtler J, Kayser K, Borkenfeld S, Carvalho R, Kayser G. Diagnostic Pathology 2017, 3:248 Large Format Histology, Whole Slide Imaging and Multi-Criteria Decision Making.* Diagnostic Pathology 2017, 3:248
185. **Cimadamore A**, Gasparrini S, Mazzucchelli R, Doria A, Cheng L, Lopez-Beltran A, Santoni M, Scarpelli M, Montironi R. *Long Non-coding RNAs in prostate cancer with emphasis on SChLAP1 expression.* Front Oncol. 2017;7:305.
186. Meletani T, Cantini L, Lanese A, Nicolini D, **Cimadamore A**, Agostini A, Ricci G, Antognoli S, Mandolesi A, Guido M, Alaggio R, Giuseppetti GM, Scarpelli M, Vivarelli M, Berardi R.

*Are liver nested stromal epithelial tumors always low aggressive?* World J Gastroenterol.2017;23(46):8248-8255.

1. Gasparrini S, **Cimadamore A**, Scarpelli M, Massari F, Doria A, Mazzucchelli R,Cheng L, Lopez-Beltran A, Montironi R. *Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians.* Asian J Androl. 2019;21,19-23. doi: 10.4103/aja.aja\_24\_17.
2. Guerra E, **Cimadamore A**, Simeone P, Vacca G, Lattanzio R, Botti G, Gatta V, D'Aurora M, Simionati B, Piantelli M, Alberti S. *p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading*. BMC Cancer. 2016;16:649.

Guest Editor

Special Issue in Current Drug Target 2020: “Current and future perspectives of the PD1/PD-L1 axis in uro-oncology”

Special Issue in Cells 2020: "Update on Prostate Cancer Diagnosis, Prognosis and Prediction to Response to Therapy"

Book chapters

* Lopez-Beltran A, Raspollini MR, Cheng L, Scarpelli M, **Cimadamore A**, Gasparrini S, Montironi R.

Chapter 19 *“Specimen handling: radical and partial nephrectomy specimens”*

Chapter *20 “Staging and reporting of renal cell carcinomas”*

in Advances Surgical Pathology “in press”

* Santoni M, **Cimadamore A**, Cheng L, Lopez-Beltran A, Scarpelli M, Battelli N, Montironi R. *Targeted treatment of renal cell carcinoma.* Kidney Cancer: Recent Advances in Surgical and Molecular Pathology, edited by Drs. Jae Ro, Mukul Divatia, Charles Guo, and Ayhan Ozcan.
* Montironi R, Mazzucchelli R, Gasparrini S, **Cimadamore A**, Galosi AB, Raspollini MR, Lopez-Beltran A, Cheng L, Scarpelli M.
  + *The Prostatic Utricle and Endometrioid Prostate Cancer: Similarities, Differences and Challenges* (Chapter 8- Section 3 Prostatic Lesions and Tumors)
  + *Biphasic Tumors of the Urogenital Tract: Selected Topics* (Chapter 10- Section 3 Prostatic Lesions and Tumors)

February 2019. DOI: 10.1017/9781316756423.010

In book: Gynecologic and Urologic Pathology, edited by Maria Rosaria Raspollini, Antonio Lopez-Beltran. Cambridge, United Kingdom; New York, NY: Cambridge University Press, 2019

* **Cimadamore A**, Montironi R. Author of **35 Chapters** in *Encyclopedia of pathology*, edited by Han van Krieken. Published by Springer Nature Switzerland AG, Gewerbestrasse 11, 6330 Cham, Switzerland., 2019
* Montironi R, Mazzucchelli R, **Cimadamore A**, Scarpelli M, Lopez-Beltran A, Cheng L. *Pathology of the benign and malignant diseases of the prostate*.

Book: Prostate MRI Essentials: A Practical Guide for Radiologists, Edited by Temel Tirkes

* Goteri G., **Cimadamore A**. (2020) *Half-Century Research and Teaching Activity in Anatomic Pathology throughout the History of Technologic Innovation.* In: Longhi S. et al. (eds) The First Outstanding 50 Years of “Università Politecnica delle Marche”. © Springer Nature Switzerland AG 2020. Print ISBN 978-3-030-33831-2 DOI:10.1007/978-3-030-33832-9\_6.
* **Cimadamore A.** *Pathology of Urinary Bladder Inverted Papilloma*. Medscape Drugs & Diseases. Updated May 12, 2021. Available at: <https://emedicine.medscape.com/article/1788400-overview>
* **Cimadamore A.,** Montironi R., Serni S., Campi R. (2020) *Seminal Vesicle Tumor Microenvironment*. In: Birbrair A. (eds) Tumor Microenvironments in Organs. Advances in Experimental Medicine and Biology, vol 1296. Springer, Cham. [https://doi.org/10.1007/978-3-030-59038-3\_19 Print ISBN 978-3-030-59037-6](https://doi.org/10.1007/978-3-030-59038-3_19%20Print%20ISBN%20978-3-030-59037-6)
* Board Editor of Klatt “Robbins e Cotran Atlante di Anatomia Patologica” Fourth Edition, Chapter 13. The Female Genital Tract.

Abstract

1. **Cimadamore A**, Lonati C, Di Trapani E, De Cobelli O, Rink M, Zamboni S, Simeone C, Soria F, Briganti A, Montorsi F, Antonelli A, Karnes RJ, Hurle R, Poyet C, D'Andrea D, Shariat SF, Sanchez-Salas R, Francavilla S, Krajewski W, Laukhtina E, Xylinas E, Rouprêt M, Montironi R, Moschini M. *The diagnostic issue of variant histologies in bladder cancer: does the centre have an impact in detection accuracy?* AUA 2022, accepted, Annual Meeting in New Orleans, LA, 13-16 May 2022.
2. **Cimadamore A**, Lonati C, Di Trapani E, De Cobelli O, Rink M, Zamboni S, Simeone C, Soria F, Briganti A, Montorsi F, Antonelli A, Karnes RJ, Hurle R, Poyet C, D'Andrea D, Shariat SF, Sanchez-Salas R, Francavilla S, Krajewski W, Laukhtina E, Xylinas E, Rouprêt M, Montironi R, Moschini M. *The diagnostic issue of variant histologies in bladder cancer: does the centre have an impact in detection accuracy?* Accepted EAU Amsterdam 18-21 March 2022
3. Leni, Scuderi S, Gandaglia G, Lucianò R, Tenace N, Paparesta F, Pepi L, Quarta L, Toneatto L, Stabile, Mazzone, Barletta, **Cimadamore A,** Montironi R, Montorsi F, Briganti A. *Does Centralized Revision of Prostate Biopsy Impact on Active Surveillance Outcomes?* Accepted EAU Amsterdam 18-21 March 2022
4. Scuderi S, Pellegrino, Lucianò R, Tenace N, Paparesta F, Pepi L, Quarta L, Toneatto L, Stabile, Mazzone, Barletta, De Angelis, Robesti, Cannoletta, Pellegrino A., Cucchiara, Leni, Gandaglia G, Stabile, **Cimadamore A**, Montironi R, Montorsi F, Briganti A. *Histological Variants of Prostate Cancer are Under-reported in Prostate Biopsies Assessed Outside Tertiary Referral Centers*. Accepted EAU Amsterdam 18-21 March 2022
5. Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Hawley J, Sosman JA, Alter R, Plimack ER, Ornstein MC, Hurwitz M, Peace D, Signoretti S, Denize T, **Cimadamore** A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. *Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final Report*. GU ASCO 2022
6. Cesari E, Tola E, Ventura F, Borgheresi A, Sternardi F, Franzese C, Montesi L, Pepi L, **Cimadamore A**, Galosi AB, Agostini A, Giovagnoni A. Valutazione dell’invasione extraprostatica in RM prostata: BPRM vs MPRM. Presentato 29 Ottobre 2021, Congresso Società Italiana di Radiologia (SIRM) interregionale, Rimini 28-30 Ottobre 2021
7. Ventura F, Tola E, Cesari E, Borgheresi A, Sternardi F, Delle Fave R, Pretore E, Pepi L, **Cimadamore A**, Galosi AB, Agostini A, Giovagnoni A. Valori predittivi di metastasi linfonodale da carcinoma della vescica in TC. Presentato 29 Ottobre 2021, Congresso Società Italiana di Radiologia (SIRM) interregionale, Rimini 28-30 Ottobre 2021
8. Sighinolfi MC, Sarchi L, Assumma S, **Cimadamore A**, Montironi R, Reggiani Bonetti L, Turri F, De Carne C, Maiorana A, Micali S, Rocco B. (Modena). *Focal secondary resection of neurovascular bundles after digital frozen section of prostate surface: a novel tailored surgical approach*. SC8 SIU Riccione 2021
9. Franzese C, Cicconofri A, Delle Fave RF, **Cimadamore A**, Pepi L, Montironi R, Galosi AB. *Variant histology of urothelial muscleinvasive bladder carcinoma and lymph node metastasis: what is the clinical relevance? – An updated study.* 31st Annual meeting of the Italian Society of Uro-Oncology (SIUrO) 30 September - 2 October 2021, Virtual Meeting
10. Pitoni L, Dell’atti L, Castellani D, Parlavecchio A, Giglioni G, Chiacchio G, **Cimadamore A**, Franzese C, Scarcella S, Montesi L, Galosi AB. *Up-grading in patients with intraductal carcinoma of the prostate: daily practice in the fusion biopsy era.* 31st Annual meeting of the Italian Society of Uro-Oncology (SIUrO) 30 September - 2 October 2021, Virtual Meeting
11. Chiacchio G, Dell’Atti L, Palagonia E, Cicconofri A, Parlavecchio A, Franzese C, Pitoni L, Castellani D, **Cimadamore A**, Montironi R, Milanese G, Galosi AB. *Intraductal carcinoma in low- and intermediate-risk prostate cancer: pathological and clinical relevance*. 31st Annual meeting of the Italian Society of Uro-Oncology (SIUrO) 30 September - 2 October 2021, Virtual Meeting
12. **Cimadamore A**, Montironi R. GUPS Case of the Week. 2021-17/ April 26.
13. Rocco BMC, Sighinolfi MC, Paterlini M, Mazzucchelli R, Lopez-Beltran A, **Cimadamore A**, Puliatti S, Eissa A, Volavsek M, Reggiani Bonetti L, Maiorana A, Sandri M, Iseppi A, Spandri V, Bertoni L, Azzoni P, Micali S, Bianchi G, Pellacani G, Montironi R. *Digital prostate biopsy: Interim analysis from an international multicentric study evaluating the role of fluorescence confocal microscopy for prostate cancer diagnosis.* Eur Urol Open Sci 2020;19(Suppl 2):e185. EAU20 Virtual Congress
14. Montesi L, Sabbatini L, Leone L, Palagonia E, Parlavecchio A, Franzese C, **Cimadamore A**, Dell'atti L, Capretti C, Papaveri A, Scarcella S, Milanese G, Montironi R, Galosi AB. *Seminal vesicle invasion in pT3bN0cM0 prostate cancer patients treated with radical prostatetectomy: Impact of Ohori patterns of invasion on biochemical recurrence.* Eur Urol Open Sci 2020;19(Suppl 2):e1379. EAU20 Virtual Congress
15. Rocco B, Sighinolfi MC, Paterlini M, Mazzucchelli R, Lopez-Beltran A, **Cimadamore A**, Puliatti S, Eissa A, Volavsek M, Reggiani Bonetti L, Maiorana A, Bozzini G, Sandri M, Iseppi A, Spandri V, Bertoni L, Azzoni P, Micali S, Bianchi G, Pellacani G, and Montironi R. *MP81-08: Digital prostate biopsy: interim analysis from an international multicentric study evaluating the role of fluorescence confocal microscopy for prostate cancer diagnosis.* The Journal of Urology April 2020, 203(4), e1239. AUA 2020
16. **Cimadamore A**, Lopez-Beltran A, Montironi R, Volavšek M. *Positive surgical margin assessment: comparison between digital and light microscopy measurement in radical prostatectomy specimens.* ESUR18 Athens, 2018
17. **Cimadamore A**, Gasparrini S, Doria A, Montironi R*. An intriguing case of testicular vascular tumor.* Annual congress of Pathological Anatomy SIAPEC-IAP 2017. Naples Oct 12-14, 2017
18. Leone L, Montesi L, Sternardi F, Palagonia E, **Cimadamore A**, Fogante M, Montironi R, Giovagnoni A, Galosi AB. *Foci index e non index di neoplasia prostatica identificati mediante macrosezioni vs RMNmp.* Congresso Nazionale SIEUN. Trieste May 3-5, 2018.
19. Palagonia E, Montesi L, Sternardi F, Leone L, **Cimadamore A**, Fogante M, Montironi R, Giovagnoni A, Galosi AB. *Analisi critica della RMNmp condotta dallo stesso radiologo prima e dopo prostatectomia radicale*. Congresso Nazionale SIEUN. Trieste May 3-5, 2018.
20. Palagonia E, **Cimadamore A**, Leone L, Piccinni P, Dell’ Atti L, Galosi AB, RMontironi R. *Lipomatosi della vescica, reinterpretazione delle immagini a seguito di referto istologico. Case Report.* Congresso Nazionale SIEUN. Trieste May 3-5, 2018.
21. **Cimadamore A.** *Cutaneous T-cell lymphoma*. Pathologica 2016;108:179,201.

Posters

1. Scuderi S, Pellegrino, Lucianò R, Tenace N, Paparesta F, Pepi L, Quarta L, Toneatto L, Stabile, Mazzone, Barletta, De Angelis, Robesti, Cannoletta, Pellegrino A., Cucchiara, Leni, Gandaglia G, Stabile, **Cimadamore A**, Montironi R, Montorsi F, Briganti A. *Histological Variants of Prostate Cancer are Under-reported in Prostate Biopsies Assessed Outside Tertiary Referral Centers***,** poster AUA 2022 Annual Meeting in New Orleans, LA, 13-16 May 2022.
2. **Cimadamore A**, Zizzi A, Pepi L, Montironi R, Scarpelli M1. *Evaluation of Prognostic Values of Perivascular Lymphocyte Cuffing and Microglia-Macrophage Infiltrate in a Series of Glioblastomas.* Poster number #1593, to the United States & Canadian Academy of Pathology’s (USCAP) 109th Annual Meeting in Los Angeles, California, February 29-March 5, 2020
3. Pecci F, Cantini L, Murrone A, Tomasetti M, Fiordoliva I, Copparoni C, Morgese F, Rinaldi S, Mazzanti P, Barbisan F, Rubini C, **Cimadamore A**, Scarpelli M, Santarelli L, Berardi R. *Questioning the prognostic role of BAP-1 in malignant pleural mesothelioma: a cohort study and meta-analysis*. European Congress Lung Cancer-Ginevra, April 2020
4. Montesi L, Leone L, Palagonia E, Sternardi F, Fogante M, **Cimadamore A**, Montironi R, Giovagnoni A, Dell’Atti L, Galosi AB. *Index and not-index lesions identified in the pathological sections and in multiparametric MRI.* Eur Urol Supplements 17 (2018), 167-374. P20. SIU Riccione Oct 13-15 2018.
5. **Cimadamore A**, Palagonia E, Leone L, Piccinni P, Dell’Atti L, Galosi AB, Montironi R. *Lipomatosi della vescica, reinterpretazione delle immagini a seguito di referto istologico. Case Report.* Congresso Nazionale SIEUN. Trieste May 3-5, 2018.
6. Gasparrini S, Zizzi A, **Cimadamore A**, Poloni A, Goteri G , Leoni P , Babini L. *A custom panel for TP53 mutations screening in heamatological malignancies by Maldi-tof Mass Spectrometry.* Annual congress of Pathological Anatomy SIAPEC-IAP 2017. Naples Oct 12-14, 2017
7. Gasparrini S, Mazzucchelli R, **Cimadamore A**, Montironi R. *The immunohistochemical evaluation of ERG expression in prostate cancer. Whole slide imaging vs. conventional microscopy.* Annual congress of Pathological Anatomy SIAPEC-IAP 2017. Naples Oct 12-14, 2017

**Conferences**

Invited speaker

1. **Cimadamore A.** “BRCA and other molecular tests in metastatic PCa”. Meeting of the Young Academic Urologists (YAU) - Special Session YAU-ESUP session: Promising tissue biomarkers and predictive molecular tests from clinical research. 38th Annual European Association of Urology (EAU) Congress (EAU23). Milan, March 10-13 2023
2. **Cimadamore A.** “Molecular genetic changes in prostate cancer: clinical implications” 53rd Professor Janez Plečnik Memorial Meeting (December 1-2 2022) Faculty of Medicine, Korytkova 2 Ljubljana.
3. **Cimadamore A.** “Molecular subtyping of urothelial carcinoma” 53rd Professor Janez Plečnik Memorial Meeting (December 1-2 2022) Faculty of Medicine, Korytkova 2 Ljubljana.
4. **Cimadamore A.** CARCINOMA PROSTATICO: DALLA BIOLOGIA ALLA CLINICA. Prato, 25 Novembre 2022. Responsabile Scientifico: Elena Zafarana. “Ruolo dell’anatomia patologica: fattori predittivi nel tumore della prostata”.
5. **Cimadamore A.** “ARTIFICIAL INTELLIGENCE and PRE-IMPLANTATION KIDNEY BIOPSIES 2.0” Bari, 21 Novembre 2022. “Confocal microscopy in uropathology: update”.
6. **Cimadamore A.** PARPi SUMMIT: Percorsi di cura practice-changing, dal test predittivo all'algoritmo terapeutico - MILANO, 03-04 Novembre 2022 – Astrazeneca.

“Diagnostic Journey per un appropriato approccio terapeutico - Moderatore: O. Caffo, Discussant R. Iacovelli, A. Lapini, A. Cimadamore

“Gestione interdisciplinare del paziente affetto da mCRPC” - Moderatore: U. De Giorgi, Discussant N. Borsellino, A. Lapini, A. Cimadamore

1. **Cimadamore A.** 9° Congresso Triennale SIAPeC-IAP 2022, Padova 12-15 Ottobre 2022. Le nuove prospettive del ruolo del patologo nella diagnostica uropatologica. “La valutazione intraoperatoria del margine chirurgico in corso di prostatectomia radicale”.
2. **Cimadamore A.** XXXII CONGRESSO NAZIONALE- SIUrO 6-8 Ottobre 2022, Firenze. Sezione: Scenari emergenti nei tumori uroteliali avanzati. “Anatomia patologica e elementi biomolecolari”.
3. **Cimadamore A.** XXXII CONGRESSO NAZIONALE- SIUrO 6-8 Ottobre 2022, Firenze. SIUrO Giovani - Intelligenza artificiale in uroncologia: chimera o realtà?. “L’intelligenza artificiale nella lettura dei preparati istologici?”
4. **Cimadamore A.** XXXII CONGRESSO NAZIONALE- SIUrO 6-8 Ottobre 2022, Firenze. SIUrO Giovani - Intelligenza artificiale in uroncologia: chimera o realtà?. “L’intelligenza artificiale nella lettura dei preparati istologici?”
5. **Cimadamore A.** NEOPLASIE DEL TRATTO UROGENITALE- Ego Hotel, Ancona, 28 settembre 2022. “Classificazione istologica-biomolecolare dei tumori della vescica”
6. **Cimadamore A.** 10th WTC-GUGO - The 10th World Top Communications of the Year in Genito-Urinary & Genomic Oncology (WTC-GUGO) - Terni – 22/23 Settembre 2022 PROSTATE CANCER. nmCRPC: Any Pathological predictor of systemic aggressiveness?
7. **Cimadamore A.** Corso asincrono XXXII Congresso Nazionale SIUrO. Carcinoma prostatico a basso rischio. “Definizioni anatomopatologica e fattori predittivi.”
8. **Cimadamore A.** Abstract presenter at EAU 2022, Amsterdam July 1- 4, 2022.
9. **Cimadamore A.** “Le novità sui tumori prostatici”. Il confine tra benigno e maligno – dalla morfologia alla patologia molecolare. Roma June 30-July 2 2022.
10. **Cimadamore A.** “Possible pathological and biomolecular background”. Section: Castration Resistant Prostate Cancer. Young Oncologists and pathologists, Multidisciplinary Team Working. Orvieto, June 14-15 2022
11. **Cimadamore A.** “Caratterizzazione ed utilizzo dei fattori molecolari nei gliomi alla luce della nuova classificazione”. Tumori cerebrali: percorsi e progressi nella rete ospedaliera marchigiana. Pesaro, June 11 2022
12. **Cimadamore A**. PD-L1 nell’urotelio. Update valutazione di PD L1: indicazioni, piattaforme diagnostiche e cloni, score e modalità di refertazione, controlli di qualità e sicurezza del processo. SIAPEC Webinar - 11 maggio 2022
13. **Cimadamore A.** Novità nella nuova edizione WHO dei tumori genitourinari. "Aggiornamenti in Anatomia Patologica", SIAPEC. Virtual, Università degli Studi di Salerno, Apr 21, 2022
14. **Cimadamore A,** Colecchia M, Lopez-Beltran A. “Prostate Cancer and Active surveillance in 2021 – Uropathology Course Workshop, Nov 25 2021, Athens – EMUC 2021 Congress
15. **Cimadamore A**. “Prostate cancer grading: Will “Gleason” survive?” EMUC Symposium on Genitourinary Pathology and Molecular Diagnostics. (ESUP). Nov 25 2021, Athens – EMUC 2021 Congress
16. **Cimadamore A**. “TNM staging towards a personalized approach: What will the future be like?” EMUC Symposium on Genitourinary Pathology and Molecular Diagnostics. (ESUP). Nov 25 2021, Athens – EMUC 2021 Congress
17. R. Montironi; **A. Cimadamore. “**Anatomopatologica per l’alto grado: con i nuovi approcci scientifici si può orientare la terapia?” SESSIONE I- TUMORE SUPERFICIALE – NMIBC

Moderatori: A. Boni; R. Hurle. Ricerca clinica e patient engagement: dalla teoria alla pratica

in uro-oncologia 2021. Congresso annuale Associazione PALINURO. Online, 20 Novembre 2021.

1. **Cimadamore A.** Sessione:Tavola rotonda: mutazioni somatiche e germinali nei tumori urologici: quando eseguire i test genetici?. Titolo presentazione: “Cancro della vescica”. 94° Congresso Nazionale Società Italiana di Urologia, Riccione 16-19 Ottobre 2021
2. **Cimadamore A.** Simposio: La medicina di precisione nel mCRPC: una nuova era. Titolo presentazione: “Il test BRCA nel tumore della prostata”. 94° Congresso Nazionale Società Italiana di Urologia, Riccione 16-19 Ottobre 2021
3. **Cimadamore A. “**Understanding pathology & biology of prostate cancer.”Sessione “IMAGIN A NEW ADVANCED PROSTATE CANCER SCENARIO” in WFRTC-GU (Watching for a - Full Residential – Top Communication in Genito-Urinary-Oncology) 9TH Edizione Terni, Oct 14 2021.
4. **Cimadamore A. “**Novità nella classificazione patologica e molecolare dei carcinoma della vescica”. Neoplasie del tratto urogenitale. Sep 24, 2021 Ancona, Mole Vanvitelliana.
5. **Cimadamore A. “**Current morphologic classification of the bladder neoplasms.” Bladder neoplasms: will a morphological classification become obsolete? Urowebinar, Virtual promoted by ESUP, ESOU, EAU Guidelines. Sep 23, 2021.
6. **Cimadamore A.** Virtual Educational Series - European Society of Pathology, AZ/MSD. "ctDNA testing for HRRm mutations in prostate cancer". <https://www.esp-pathology.org/educational-portal/virtual-educational-series.html>
7. **Cimadamore A. “**Donald Gleason - more than an acronym”. Joint Short Course History of Pathology / Uropathology: Historical figures of uropathology. European Congress of Pathology, Virtual. Aug 31, 2021
8. **Cimadamore A**. “Patologia digitale in uropatologia: l’impiego della metodica confocale”. Webinar - Impiego e prospettive della digital pathology in patologia urologica. May 10, 2021
9. **Cimadamore A. “**Basi genomiche del carcinoma prostatico: quali certezze e su quale materiale?” MAXI-GUMM, Virtual Meeting, Feb 18-19 2021.
10. **Cimadamore A.** Slide Seminar Uropathology / Soft Tissue and Bone Pathology: “Spindle cell lesions”. Dec 8, 2020 32nd European Congress of Pathology and the XXXIII International Congress of the International Academy of Pathology (IAP), Glasgow, Virtual Congress
11. **Cimadamore A. “**Grading group risk nell’adenocarcinoma della prostata: pro and cons”. GU2 Nuove sfide nella terapia dei tumori GU. Virtual, Dec 3 2020.
12. **Cimadamore A,** Montironi R. “Biopsia prostatica e risonanza magnetica multiparametrica – Gleason score, Grade Grouping and PIRADS”. Dec 2, Virtual meeting SIU, Società italiana di Urologia.
13. **Cimadamore A. “**La classificazione molecolare dei carcinomi vescicali”. Virtual Meeting “Gruppi di miglioramento – Formazione sul Campo”, Rete Oncologica del Piemonte e della Valle d’Aosta, Nov 25, 2020.
14. **Cimadamore A**, Montironi R. “Il ruolo dell’anatomo patologo nel 2020” - Ricerca clinica e patient engagement, Virtual meeting – Associazione PaLiNUro, Nov 14, 2020
15. ERUS-DRUS20 Virtual Meeting 6-7 November 2020: consultant pathologist **Cimadamore A**: FCM margin assessment during live surgery
16. **Cimadamore A.** “Index lesion e terapia focale: razionale anatomo-patologico”. E-learning FAD - LIVE - Terapie Ablative nel trattamento del carcinoma prostatico e renale – Oct 10, 2020
17. **Cimadamore A.** Choueiri’s Lab Meeting – Dana Farber Cancer Institute. Spatial analysis on AtezoBev trial 15-592. Oct 8, 2020
18. **Cimadamore A**. mHSPC: Next Generation Pathology: Which data? Next Generation WTC-GU Webinar, 1 Oct 2020.
19. **Cimadamore A.** “Basi patologiche e biomolecolare nel tumore della prostata”.Immunoterapia nel carcinoma prostatico. SIURO 2020 Virtual Meeting – 28 Sept 2020
20. Videochirurgia urologica Live – Peschiera del Garda, Sep 17, 2020. Confocal microscopy margin assessment during radical prostatectomy. Prof. Rocco B. (Consultant Pathologist: **Cimadamore A.**)
21. **Cimadamore A.** “Il nuovo ruolo del BRCA nel carcinoma prostatico”Incontri e dibattiti sui tumori uro-ginecologici - Bari, 4-5 Sept 2020
22. 7th Meeting of the EAU Section of Uro-Technology (ESUT) Leipzig, 23-24 Gennaio 2020- consultant pathologist **Cimadamore A**: FCM margin assessment during live surgery (remotely from Boston).
23. **Cimadamore A**. “Genetic profile e implicazioni terapeutiche”. Terapia personalizzata dell’adenocarcinoma prostatico. Terapia personalizzata nell’adenocarcinoma della prostata. Reggio Emilia Nov 12, 2019.
24. **Cimadamore A.** “Live surgery (robotic radical prostatectomy) and demonstration of FCM for digital frozen section of the postero-lateral aspect of the prostate (Mohs section)”. Modena Nov 8, 2019
25. **Cimadamore A**. “Best abstract ECP in prostatic pathology.” Uropathology session. 8th Congress of Pathological Anatomy SIAPEC-IAP 2019. Turin Oct 18, 2019
26. **Cimadamore A**. “Case presentation in Uropathology.” Uropathology session. 8th Congress of Pathological Anatomy SIAPEC-IAP 2019. Turin Oct 18, 2019.
27. **Cimadamore A**. “Nodal IgG4 positive atypical plasma cell proliferation”. Hematopathology session. 8th Congress of Pathological Anatomy SIAPEC-IAP 2019. Turin Oct 16, 2019
28. **Cimadamore A**. “Any relevant genomic issue in localized prostate cancer setting?” 7th World Top Communications of the Year in Genito-Urinary Oncology - Terni, Oct 9/10, 2019
29. **Cimadamore A**. “Glandular lesion and tumours in Uropathology – Videomicroscopy session.” European Congress of Pathology, Nice, France. Sep 10, 2019.
30. **Cimadamore A**. “The relationship between the gut microbiota and immunotherapeutic response”. – Are we ready to bring immuno-oncology biomarkers to the clinic? Kuala Lumpur, Malaysia. June 29-30, 2019.
31. **Cimadamore A**. “Nuovi orizzonti nella classificazione molecolare del carcinoma vescicale:

l'alba della personalizzazione del trattamento”. XXIX Congresso Nazionale SIUrO. Bologna, Apr 13, 2019.

1. **Cimadamore A**. “Case presentation: Aberrant p63 positive prostate adenocarcinoma; PIN-like carcinoma”. Orbassano, Uropathology Workshop. Jan 24, 2019.
2. **Cimadamore A**. “Case presentation: Complete regression of muscle-invasive bladder cancer after neoadjuvant chemotherapy” ASSUAM (Associazione di Urologia e Andrologia delle Marche), Università Politecnica delle Marche, Jan 25, 2019.
3. **Cimadamore A**. “Histologic and molecular classification of astrocytic brain tumors”. Cerebral tumors in Marche Region. Pesaro Jun 10, 2017.
4. **Cimadamore A**. “Case presentation: Cutaneous T-cell lymphoma”. 7th congress of Pathological Anatomy SIAPEC-IAP 2016. Genova Nov 23-26, 2016
5. **Cimadamore A**. “Molecular pathology and prostate cancer with emphasis on non-coding RNA SChLAP1 expression”. Uro-oncology update. Ancona Mar 10, 2017

Invited Moderator

* **Cimadamore A.** Moderator and panelist of Special Session YAU-ESUP session: Promising tissue biomarkers and predictive molecular tests from clinical research. 38th Annual European Association of Urology (EAU) Congress (EAU23). Milan, March 10-13 2023
* **Cimadamore A.** Chair of “Cell biology and novel therapies in prostate cancer - Abstract Session 61”. 38th Annual European Association of Urology (EAU) Congress (EAU23). Milan, March 10-13 2023
* **Cimadamore A,** Barbisan F, Ballatore Z. Le neoplasia toraciche: dalla biologia alla pratica clinica. IMPLEMENTAZIONE DEI MOLECULAR TUMOR BOARD (MTB) presented by Nicola Normanno. Ancona, Oct 29, 2021
* **Cimadamore A**, Joze Pizem. Session “ADVANCES IN PROSTATE CANCER” at 53rd Professor Janez Plečnik Memorial Meeting (December 1-2 2022) Faculty of Medicine, Korytkova 2 Ljubljana

Oral presentation

1. **Cimadamore A**. “Positive surgical margin assessment: comparison between digital and light microscopy measurement in radical prostatectomy specimens.” ESUR18 Athens Oct 4-6, 2018
2. **Cimadamore A**. “An intriguing case of testicular vascular tumor”. Annual congress of Pathological Anatomy SIAPEC-IAP 2017. Naples Oct 12-14, 2017
3. **Cimadamore A**. “The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by the international TILs Working Group 2014”. Breast Unit, Journal club. Ancona Oct 27, 2016
4. **Cimadamore A**. “My preferred Prostate &Testicular Abstracts at last EU/US Pathology Meetings”. Arezzo 5th world top communication of the year in genito-urinary oncology. Nov 16-18, 2016

**Teaching activity:**

Since 2021-current:

* Corso di Insegnamento Modulo Mod. III di Diagnostica Molecolare – Corso Integrato di Diagnostica Molecolare. Corso di Laurea Triennale in Biotecnologie, Anno 2022-2023. Carico didattico: 20h, 2CFU -Università degli Studi di Udine.
* Modulo di Anatomia Patologica – Corso Integrato di Anatomia Patologica, 12.5 ore, 1 CFU, Corso di Laurea in Medicina e Chirurgia -Università degli Studi di Udine.
* Modulo di Anatomia Patologica: patologia cardiovascolare – Corso integrato di Anatomia patologica, 12 ore, 2CFU, Scuola di Specializzazione in Anatomia Patologica -Università degli Studi di Udine.
* Modulo di Anatomia Patologica: nefropatologia – Corso integrato di Anatomia patologica, 12 ore, 2CFU, Scuola di Specializzazione in Anatomia Patologica -Università degli Studi di Udine.
* Docente della Scuola di Specializzazione di Urologia, Università Politecnica delle Marche. Carico didattico: 10h.
* Corso insegnamento Anatomia Patologica, Laurea Magistrale Ciclo Unico 6 anni - MEDICINA E CHIRURGIA, Università Politecnica delle Marche, Anno di corso: 5 - Primo Semestre. Anno offerta: 2021-2022. Carico didattico: 20h.
* Corso insegnamento Anatomia Patologica Sistematica, Laurea - Tecniche di laboratorio biomedico (abilitante alla professione sanitaria di Tecnico di laboratorio biomedico), Università Politecnica delle Marche, Anno di corso: 2 - Secondo Semestre. Anno offerta: 2021-2022. Carico didattico: 20h.
* Internato di Anatomia Patologica, Laurea Magistrale Ciclo Unico 6 anni - MEDICINA E CHIRURGIA. Università Politecnica delle Marche, Anno di corso: 5 - Secondo Semestre, Anno offerta: 2021-2022. Carico didattico: 25h.

**Seminars:**

1. “ctDNA testing in prostate cancer”. Seminario della Scuola di Dottorato in Scienze Biomediche, Ancona. Mar 12,2021.
2. E-learning- Corso di Laurea in Medicina e Chirurgia, V anno. Anatomia Patologica, topics: variants of bladder cancer, variant of prostate cancer, mimickers of prostate cancer, new entities of renal cell carcinoma.
3. **“**Spatial relationship between immune cells and tumor cells in renal cell carcinoma”.Seminario della Scuola di Dottorato in Scienze Biomediche, Ancona. Jun 03,2020.
4. “The relationship between the gut microbiota and immunotherapeutic response” Seminario della Scuola di Dottorato in Scienze Biomediche, Ancona. Jul 05,2019.
5. “Biopsia liquida e carcinoma renale: ruolo diagnostico, prognostico e predittivo.” Seminario della Scuola di Dottorato in Scienze Biomediche, Ancona, Apr 24,2019.
6. “Glioblastoma con ricco infiltrato infiammatorio”. Diagnostica istopatologica delle neoplasie cerebrali. Didactic lectures. Bologna Apr 27-28, 2017
7. “Sampling and reporting pelvic lymph nodes in prostate cancer”. Didactic lectures. Bologna May 19-20, 2016

**Member of Degree Committee** Faculty of Medicine and Surgery, Polytechnic University of the Marche Region, Ancona, Italy, June 22 2021

**Ad hoc reviewer of grant proposals**

National Science Center Poland (NCN), October 2019.

Swiss Cancer League, March 2020

Czech Science Foundation (GACR), August 2020

“Personalized Health and Related Technologies” of the ETH Domain ([www.sfa-phrt.ch](http://www.sfa-phrt.ch)), June 2021

**Ad hoc reviewer for peer reviewed journals:** European Urology Oncology, Cells, Cancers,Diagnostics**,** Virchow Archives, Histopathology, Annals of Surgical Oncology, Translational Andrology and Urology, Journal of Clinical Pathology, Frontiers in Oncology, Frontiers in Surgery, Cancer Medicine, The International Journal of Biological Markers, Cellular and Molecular Life Science, International Workshop of medicine and healthcare 2018, International Brazil J Urol, Expert Review Molecular Diagnostic, Annals of Medical & Surgical Case Reports, Drug of Today, Drug in Context, ESGO-ESTRO-ESP Endometrial Cancer Guidelines – External Reviewer, Elsevier Book proposal.

**Associate Editor** for Frontiers in Oncology

**Editorial Board Member** for Expert Review of Precision Medicine and Drug Development

**Courses and Classes**

* Genetica e genomica in oncologia: Esperti a confronto. Virtual Event, 29 Sept 2020
* Biomedical Research Investigators. CITI Program Course, under requirements set by Harvard University, Record ID 34330449
* Biomedical Research Investigators and Key Personnel. CITI Program Course, under requirements set by Brigham and Women's Hospital, Record ID 34330495
* USCAP eLearning: Intraductal Proliferative Lesions, Microinvasion, and Columnar Cell Lesions. Prof. Stuart Schnitt.
* 7th World Top Communications of the Year in Genito-Urinary Oncology. Terni, Oct 9-10, 2019.
* European Congress of Pathology, Sep 7-11 2019, Nice.
* Advances in Oncologic Pathology, Padua, May 13-17 2019. Scientific supervisor: Angelo Paolo dei Tos, Fletcher C.
* Surgical Pathology for the Practicing Pathologist - Harvard Medical School,Boston, Oct 31- Nov 4, 2016.
* XXIX Congresso Nazionale SIUrO, Bologna, Apr 11-13, 2019.
* Spring School on Prostate carcinoma – Siuro – Cortefranca, Jun 14-16, 2018
* Genitourinary tract tumors. An update in the Era of Personalized Therapy.Focus on emerging topics in kidney, urinary tract and uterus.Florence, 31st May - 1st June, 2018.
* Mesenchymal tumor course. Scientific supervisor: Angelo Paolo dei Tos. Genova, Apr 16-17, 2018
* Milan uropathology course. Kidney tutorial course - the challenging era of Immunotherapy. Milan, Mar 5-6, 2018
* Annual congress of Pathological Anatomy SIAPEC-IAP 2017. Naples, Oct 12-14, 2017
* II GIPAD-GIRCG course. The standardization of the histopathologic report. Forlì, May 26, 2017.
* Master course: Management of patients with melanoma, from research to therapy. Recanati, May 12-13, 2017.
* 7th Congress of Pathological Anatomy SIAPEC-IAP 2016. Genova, Nov 23-26, 2016
* 5th World top communication of the year in Genito-Urinary Oncology. Arezzo, Nov 16-18, 2016.
* “Il confine tra benigno e maligno: dalla morfologia alla patologica molecolare” Naples, Mar 16-18, 2016.
* Neuropathology Italian Group Meeting (GINP). Rome, Feb 12, 2016.
* Lymphopathology course. Siena, Dec 14-16, 2015
* Multidisciplinary management in the personalized treatment of breast cancer. Bologna, Dec 3-4, 2015.
* Advances in Uropathology – Gladell Paner. Ancona, Sep 22, 2015.
* GeorgetownX's Genomic Medicine Gets Personal - Edx-Course at Georgetown University – 2014.

**Event organizer**

*Tipizzazione molecolare del carcinoma polmonare non a piccole cellule (NSCLC).* Dr. Antonio Zizzi. May 29, 2019. Ancona

*Prostate Cancer: what’s new, true and important.* Prof. Cristina Magi-Galluzzi. Jun 10,2019. Ancona

**Membership and associations**

* Member of Board of the EAU Section of Uropathology (ESUP), as Ex-Officio Member on behalf of YAU since January 2023.
* Member of the Urothelial Cancer Working Party – Young Academic Urologists (YAU)- European Association of Urologists (EAU) since January 2021
* Member of European Society of Pathology (ESP). Working groups: Uropathology and Gynecological pathology - since April 2018
* Associate Member European Society Uropathology (ESUP) – since March 2020
* Member of Società Italiana di Anatomia Patologica e Citologia (SIAPEC) - since December 2015
* Member of International Society of Urological Pathology (ISUP) – since December 2016
* Member of Genitourinary Pathology Society (GUPS) – since September 2018
* Member of Italian Society of Uro-Oncology (SIUrO) - since May 2018
* Member of United States and Canadian Academy of Pathology (USCAP) – since October 2019
* Member of the Scientific Committee of the Italian Innovators in Multidisciplinary & Genito-Urinary Oncology (ImGO)

Autorizzo il trattamento dei miei dati personali presenti nel cv ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 “Codice in materia di protezione dei dati personali” e dell’art. 13 del GDPR (Regolamento UE 2016/679).

March, 2023